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Abstract  
 Somatic mutations in the tumour suppressor gene TP53 occur in more than 50% of human 
tumours; in some instances exposure to environmental carcinogens can be linked to characteristic 
mutational signatures. The Hupki (human TP53 knock-in) mouse embryo fibroblast (HUF) 
immortalisation assay (HIMA) is a useful model for studying the impact of environmental 
carcinogens on TP53 mutagenesis. In an effort to increase the frequency of TP53-mutated clones 
achievable in the HIMA, we generated nucleotide excision repair (NER)-deficient HUFs by 
crossing the Hupki mouse with an Xpa-knockout (Xpa-Null) mouse. We hypothesized that 
carcinogen-induced DNA adducts would persist in the TP53 sequence of Xpa-Null HUFs leading to 
an increased propensity for mismatched base pairing and mutation during replication of adducted 
DNA. We found that Xpa-Null Hupki mice, and HUFs derived from them, were more sensitive to 
the environmental carcinogen benzo[a]pyrene (BaP) than their wild-type (Xpa-WT) counterparts. 
Following treatment with the reactive metabolite of BaP, benzo[a]pyrene-7,8-diol-9,10-epoxide 
(BPDE), Xpa-WT and Xpa-Null HUF cultures were subjected to the HIMA. A significant increase 
in TP53 mutations on the transcribed strand was detected in Xpa-Null HUFs compared to Xpa-WT 
HUFs, but the TP53-mutant frequency overall was not significantly different between the two 
genotypes. BPDE induced mutations primarily at G:C base pairs, with approximately half occurring 
at CpG sites, and the predominant mutation type was G:C>T:A in both Xpa-WT and Xpa-Null 
cells. Further, several of the TP53 mutation hotspots identified in smokers’ lung cancer were 
mutated by BPDE in HUFs (codons 157, 158, 245, 248, 249, 273). Therefore, the pattern and 
spectrum of BPDE-induced TP53 mutations in the HIMA are consistent with TP53 mutations 
detected in lung tumours of smokers. While Xpa-Null HUFs exhibited increased sensitivity to 
BPDE-induced damage on the transcribed strand, NER-deficiency did not enhance TP53 
mutagenesis resulting from damage on the non-transcribed strand in this model. 
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1. Introduction 
 The tumour suppressor p53 plays a crucial role in the DNA damage response, garnering the 
title ‘guardian of the genome’ [1]. A paramount function of p53 is to prevent DNA synthesis and 
cell division, or to promote apoptosis, following DNA damage, which it performs primarily by 
regulating a large network of transcriptional targets [2, 3]. Disruption of the normal p53 response by 
TP53 mutation contributes to transformation by eliminating a key pathway of cellular growth 
control, enabling the survival and proliferation of stressed or damaged cells. Somatic mutations in 
TP53 occur in more than 50% of human cancers [4, 5]. The majority of TP53 mutations are 
missense and occur between codons 125 and 300, corresponding to the coding region for the DNA 
binding domain [6]. Over 28,000 TP53 mutations from human tumours have been catalogued in the 
International Agency for Research on Cancer (IARC) TP53 mutation database, providing a key 
resource for studying the patterns and frequencies of these mutations in cancer [7]. Interestingly, 
exposure to some environmental carcinogens can be linked to characteristic signatures of mutations 
in TP53, which provide molecular clues to the aetiology of human tumours [8]. 
 A useful model for studying human TP53 mutagenesis is the partial human TP53 knock-in 
(Hupki) mouse, in which exons 4-9 of human TP53 replace the corresponding mouse exons [9]. The 
Hupki mouse and Hupki mouse embryo fibroblasts (HUFs) have been used for both in vivo and in 
vitro studies of TP53 mutations induced by environmental carcinogens [10, 11]. TP53 mutagenesis 
can be studied in cell culture using the HUF immortalisation assay (HIMA). In this assay primary 
HUFs are first treated with a mutagen to induce mutations. The treated cultures, along with 
untreated control cultures, are then serially passaged under standard culture conditions, whereby the 
majority of HUFs will undergo p53-dependent senescent growth arrest, due to the sensitivity of 
mouse cells to atmospheric oxygen levels (20%). HUFs that have accumulated mutagen-induced or 
spontaneous mutations (e.g. in TP53) that enable bypass of senescence continue to proliferate and 
ultimately become established into immortalised cell lines. DNA from immortalised HUF clones is 
then sequenced to identify TP53 mutations. Environmental carcinogens that have been examined 
using the HIMA include ultraviolet (UV) radiation [12], benzo[a]pyrene (BaP) [13, 14] and 
aristolochic acid I (AAI) [12, 15]; in all cases the induced TP53 mutation pattern corresponded to 
the pattern found in human tumours from patients exposed to these mutagens.  
To protect the genome from mutation, several efficient mechanisms exist in cells to repair 
damage to DNA. One key repair system responsible for removing damage induced by certain 
environmental carcinogens is the nucleotide excision repair (NER) pathway. NER removes several 
types of structurally distinct DNA lesions including UV-induced photolesions, intrastrand 
crosslinks and chemically-induced bulky DNA adducts, such as those formed after exposure to 
polycyclic aromatic hydrocarbons (PAHs) [16]. NER operates in two distinct subpathways: global 
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genomic NER (GG-NER) that recognises lesions that cause local structural distortions in the 
genome, and transcription-coupled NER (TC-NER) that responds to lesions that block the 
progression of RNA polymerase II (RNAPII) on the transcribed strand of transcriptionally active 
genes. Following damage recognition, a common set of factors are recruited that ultimately incise 
the DNA 5’ and 3’ to the lesion to remove a 24-32 nucleotide fragment. The undamaged strand 
serves as a template for replicative DNA polymerases to fill the gap, which is finally sealed by 
ligation [17]. 
  Mouse models deficient in various NER components have been generated not only to study 
the role of NER in the repair of different types of damage and ascertain how this relates to cancer 
risk [18, 19], but also to increase the sensitivity of carcinogenicity studies [20]. For example, Xpa-
knockout (Xpa-Null) mice, or cells derived from them, are deficient in both GG-NER and TC-NER. 
Xpa-Null mice are highly sensitive to environmental carcinogens [18, 21] and exhibit accelerated 
and enhanced tumour formation after treatment with carcinogens such as UV and PAHs like BaP, 
compared with wild-type (Xpa-WT) mice  [19, 22, 23]. Increased mutation frequencies of a lacZ 
reporter gene have been measured in tissues from Xpa-Null mice treated with the aforementioned 
carcinogens, and an increased rate of p53-mutated foci was detected on the skin of Xpa-Null 
Trp53(+/-) mice exposed to UVB  [21, 22, 24]. Further, in in vitro studies, cells with reduced or 
deficient repair capacity were also more sensitive to the lethal or mutagenic effects of DNA damage 
[18, 25, 26]. 
 Here we have generated an Xpa-deficient Hupki mouse strain with the aim of increasing TP53 
mutation frequency in the HIMA. As Xpa-Null cells are completely deficient in NER, we 
hypothesized that carcinogen-induced DNA adducts would persist in the TP53 sequence of Xpa-
Null HUFs, leading to an increased propensity for mismatched base pairing and mutation during 
replication of adducted DNA [24, 27]. In the present study primary Xpa-WT and Xpa-Null HUFs 
were treated with benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE), the activated metabolite of the 
human carcinogen BaP [28, 29], which forms pre-mutagenic BPDE-DNA adducts (i.e. 10-
(deoxyguanosin-N
2
-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene [BPDE-N
2
-dG]) that 
can be removed by NER (Fig. S1) [30]. BPDE-treated HUFs were subjected to the HIMA and TP53 
mutations in immortalised clones were identified by direct dideoxy sequencing of exons 4-9. The 
induced TP53 mutation patterns and spectra were compared between the two Xpa genotypes and to 
mutations found in human tumours.  
5 
 
2. Materials and Methods 
 
2.1. Carcinogens 
 BaP (#B1760) was purchased from Sigma-Aldrich. For in vitro treatments, BaP was dissolved 
in DMSO (Sigma #D2650) to a stock concentration of 1 mM and stored at –20°C. For in vivo 
treatments, BaP was dissolved in corn oil at a concentration of 12.5 mg/mL. BPDE was synthesised 
at the Institute of Cancer Research (London, UK) using a previously published method [31]. BPDE 
was dissolved in DMSO to a stock concentration of 2 mM under argon gas and stored at –80°C in 
single-use aliquots. 
 
2.2. Details of mouse strains and crossbreeding 
 Hupki mice (Trp53
tm1/Holl 
(Arg/Arg codon 72), homozygous for a knock-in TP53 allele 
harbouring the wild-type human
 
TP53 DNA sequence spanning exons 4–9) in the 129/Sv 
background [9] were kindly provided by Monica Hollstein (German Cancer Research Center; 
Heidelberg, Germany). Transgenic Xpa
+/-
 mice, heterozygous for the Xpa-knockout allele on a 
C57Bl/6 background [18, 22] were obtained from the National Institute for Public Health and the 
Environment (Bilthoven, The Netherlands). In the Xpa-knockout allele, exon 3, intron 3 and exon 4 
have been replaced by a neomycin resistance cassette with a PGK2 promoter. To generate Hupki 
mice carrying an Xpa-knockout allele, Hupki
+/+
 mice were first crossed with Xpa
+/-
 mice. Progeny 
with the Hupki
+/-
;Xpa
+/-
 genotype were then backcrossed to Hupki
+/+
 stock to generate Hupki
+/+
 
animals that were Xpa
+/+
 or Xpa
+/-
. Hupki
+/+
;Xpa
+/-
 and Hupki
+/+
;Xpa
+/+
 offspring were thereafter 
intercrossed to maintain the colony and produce Xpa
+/+
 and Xpa
-/-
 (referred to here as Xpa-WT and 
Xpa-Null, respectively) mice and embryos for experiments. Animals were bred at the Institute of 
Cancer Research in Sutton, UK and kept under standard conditions with food and water ad libitum. 
All animal procedures were carried out under license in accordance with the law and following 
local ethical review. 
 
2.3. Genotyping 
 The Hupki and Xpa genotype was determined in mouse pups or embryos by PCR prior to 
experiments. To extract DNA for genotyping, ear clips or cells were suspended in 400 µL of 50 mM 
NaOH and heated to 95°C for 15 min. Next, 35 µL of 1 M Tris-HCl (pH 8.0) was added to each 
sample, followed by centrifugation for 20 min at 13,000 rpm. The supernatant was used for 
genotyping. Primers and PCR reaction conditions for the Hupki, mouse Trp53 or Xpa alleles are 
described in Table S1.  
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2.4. In-vivo carcinogen treatment 
 Female Xpa-WT and Xpa-Null Hupki mice (~3 months old) were treated with BaP as indicated 
below and sacrificed either 24 hr or 5 days after the last administration following treatment 
regimens published previously [28, 32]. Several organs (liver, lung, small intestine, spleen, colon 
and kidney) were removed, snap frozen in liquid N2, and stored at −80°C until analysis. 
 In the first experiment, three groups of animals (n = 3, each group) were treated orally with 125 
mg/kg bw of BaP. Groups 1 and 2 received a single dose and Group 3 was dosed once daily for 5 
days. Groups 1 and 3 were sacrificed 24 hr after the last administration, and Group 2 was sacrificed 
5 days after the last administration. In the second experiment, two groups of animals (Group 4 and 
5; n = 3, each group) were treated with 12.5 mg/kg bw BaP. Group 4 was treated with a single dose 
and sacrificed 24 hr later. Group 5 was dosed once daily for 5 days and sacrificed 24 hr after the last 
administration. Matched control mice (n = 3) for each group received corn oil only. DNA adduct 
formation was assessed as described below. 
 
2.5. DNA adduct analysis by 
32
P-postlabelling  
 Genomic DNA was isolated from cells or tissue by a standard phenol/chloroform extraction 
method and stored at –20°C. DNA adducts were measured in each DNA sample using the nuclease 
P1 enrichment version of the 
32
P-postlabelling method [33]. Briefly, DNA samples (4 μg) were 
digested with micrococcal nuclease (120 mU; Sigma, #N3755) and calf spleen phosphodiesterase 
(40 mU; Calbiochem, #524711), enriched and labelled as reported [28, 34]. Solvent conditions for 
the resolution of 
32
P-labelled adducts on polyethyleneimine-cellulose (PEI) thin-layer 
chromatography (TLC) were: D1, 1.0 M sodium phosphate, pH 6; D3, 4.0 M lithium-formate, 7.0 
M urea, pH 3.5; D4, 0.8 M lithium chloride, 0.5 M Tris, 8.5 M urea, pH 8. After chromatography 
TLC plates were scanned using a Packard Instant Imager (Dowers Grove, IL, USA). DNA adduct 
levels (RAL, relative adduct labelling) were calculated from adduct counts per minute (cpm), the 
specific activity of [-32P]ATP (Hartmann Analytic #HP601ND) and the amount of DNA (pmol) 
used. Results were expressed as DNA adducts/10
8
 normal nucleotides (nt). An external BPDE-
modified DNA standard was used for identification of BaP-DNA adducts. 
 
2.6. Isolation of primary mouse embryonic fibroblasts 
 Xpa-WT and Xpa-Null Hupki mouse embryonic fibroblasts (HUFs) were isolated from day 
13.5 embryos of intercrosses of Hupki
+/+
;Xpa
+/-
 mice according to a standard procedure. Briefly, 
neural and haematopoietic tissues were removed from each embryo by dissection and the remaining 
tissue was digested in 1 mL of 0.05% trypsin-EDTA (Invitrogen #25300-062) at 37°C for 30 min. 
The resulting cell suspension from each embryo was mixed with 9 mL of growth medium 
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(Dulbecco’s modified medium (Invitrogen #31966-021) supplemented with 10% fetal bovine serum 
(Invitrogen #26140-079) and 100 U/mL penicillin and streptomycin (Invitrogen #15140-130)), 
pelleted at 1000 rpm for 5 min, and then transferred into a 175-cm
2
 tissue-culture flask containing 
35 mL of growth medium. Cells were cultured to 80-90% confluence at 37°C/5% CO2/3% O2 
before preparing frozen stocks (passage 0; approximately 3 days). Fibroblast cultures were 
genotyped as described above. 
 
2.7. Culture of HUFs and growth curves  
 HUFs were cultured in growth medium (see 2.6) at 37°C/5% CO2 with either 20% or 3% O2, 
adjusted using an incubator fitted with an oxygen sensor and a nitrogen source. All manipulations 
conducted outside the incubator were performed at 20% O2. For passaging, cells were detached with 
0.05% trypsin-EDTA for 2–3 min, suspended in growth media and reseeded at the desired cell 
number or dilution. When required, cells were counted using an Improved Neubauer 
Hemacytometer according to the manufacturer’s instructions.  
 Mammalian cell culture, including that of HUFs, typically takes place in incubators containing 
ambient air buffered with 5–10% CO2, which contains a much higher level of oxygen (20%) than 
the concentration to which tissues are exposed in vivo. The mean tissue level of oxygen is variable, 
but is typically about 3%, and mean oxygen tension in an embryo may be even less [35]. Mouse 
cells are more sensitive than human cells to growth at 20% O2, whereby they accumulate more 
DNA damage and respond by entering senescence within two weeks of culture [36, 37]. While this 
is required for the selective growth of TP53-mutated clones in the HIMA, it also limits the number 
of primary cells available for experiments prior to initiating an assay (e.g. optimising carcinogen 
treatment conditions). It was shown previously that culture-induced senescence of primary mouse 
embryo fibroblasts (MEFs) could be inhibited by growing cells in 3% (physiological) oxygen [37]. 
 To compare the growth of HUFs at atmospheric or physiological oxygen levels, passage 0 
primary HUFs (Xpa-WT and Xpa-Null) were thawed and cultured in either 20% O2 or 3% O2. After 
48 hr, the cells were trypsinised and counted. Cells (2.5  105) were reseeded into 25-cm2 flasks and 
again incubated at either 20% or 3% O2. Cells were counted every 3–4 days and reseeded at 2.5  
10
5 
cells/25-cm
2
 flask for several weeks. Cultures in 3% O2 began to proliferate more rapidly after 
~3 weeks in culture and were subsequently reseeded at 0.8–1.2  105 cells/25-cm2 flask. Cultures in 
20% O2 began to populate with spontaneously immortalised, faster growing cells after 30–40 days 
and were subsequently reseeded at 0.8–1.2  105 cells/25-cm2 flask. 
 The fold-population increase (PI) was calculated each time cells were counted (# of cells 
counted / # of cells seeded = PI1, PI2, etc.) and was used to calculate the cumulative population 
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increase (CumPI): CumPI1 = PI1, CumPI2 = PI1 * PI2, CumPI3 = PI1 * PI2 * PI3, etc. The 
cumulative population increase was then used to calculate the cumulative population doubling 
(CumPD): CumPD1 = log2 (CumPI1), CumPD2 = log2 (CumPI2), etc. 
 
2.8. Crystal violet staining assay for cell survival 
 The crystal violet staining assay [38] was used to determine relative cell survival following 
BaP or BPDE treatment, compared with control (untreated) cells. Cells were seeded on 96-well 
plates at 2.5–5.0  103/well and treated the following day with BaP (24 or 48 hr) or BPDE (2 hr) 
diluted in growth medium to a highest final concentration of 1 µM (0.1% DMSO final). BPDE 
treatment media was replaced after 2 hr with normal growth media. Treatment was performed in 5 
replicate wells per condition at 37°C/5% CO2/3% O2. At 24 or 48 hr following initiation of 
treatment, cells were rinsed with PBS and adherent cells were fixed and stained for 15 min with 
0.1% (w/v) crystal violet (Sigma #C3886) in 10% ethanol. Cells were gently washed with PBS to 
remove excess crystal violet and allowed to dry. For quantification, the dye was solubilised in 50% 
ethanol (100 µL per well) and absorbance at 595 nm was determined using a plate reader. Data are 
presented as the amount of absorbance in wells of treated cells relative to that of DMSO-treated 
cells and are representative of at least three independent experiments. The linearity of this method 
was confirmed for subconfluent HUF cultures (data not shown). 
 
2.9. Carcinogen treatment of HUFs for DNA adduct analysis 
 The day prior to treatment, primary HUFs (Xpa-WT and Xpa-Null) were seeded so as to be 
sub-confluent at the time of harvest. For BaP treatment, 1.5  106 or 1.0  106 cells were seeded 
into 75-cm
2
 flasks for treatments of 24 or 48 hr, respectively. For BPDE treatment (up to 2 hr), cells 
were seeded at 2.0–2.5  106 cells into 75-cm2 flasks. Duplicate flasks were treated for each 
condition. BaP and BPDE were diluted in growth medium to a highest final concentration of 1 µM 
(0.1% DMSO final). Cells were incubated with BaP at 37°C/5% CO2, in either 20% or 3% O2, or 
with BPDE at 37°C/5% CO2/3% O2. Cells grown in medium containing 0.1% DMSO served as 
control. In the BPDE-DNA adduct removal experiment, treatment medium was removed after 2 hr 
and replaced with fresh growth medium. Cells were harvested following the indicated incubation 
time (BaP: 24 or 48 hr; BPDE: 0.5, 2 or 6 hr) and stored as pellets at –20°C until analysis. DNA 
adduct formation was assessed as described above. 
 
2.10. Hupki mouse embryo fibroblast immortalisation assay (HIMA) 
 Immortalisation of primary Hupki mouse embryo fibroblasts treated with BPDE was 
performed twice (HIMA 1 and 2), according to previously published protocols [15, 39]. Frozen 
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Xpa-WT and Xpa-Null primary HUFs (passage 0) were thawed and seeded into 175-cm
2
 flasks at 
37°C/5% CO2/3% O2 for expansion. After 3 days, cells were trypsinised, counted and seeded 
(passage 1) at 2.0 × 10
5
 cells/well into 6-well Corning CellBind
®
 plates. Cells were treated the 
following day with 0.5 µM BPDE (for each Xpa genotype, HIMA 1: 48 cultures; HIMA 2: 54 
cultures) or 0.1% DMSO (for each Xpa genotype, HIMA 1: 24 cultures; HIMA 2: 30 cultures) for 2 
hr.  
 Following treatment, as the cells approached confluence, the HUFs were subcultured on 6-well 
Corning CellBind
®
 plates at a dilution of 1:2–1:4. After a further 4 days, all cultures were 
transferred to 20% O2 to select for senescence bypass. Cultures were passaged once or twice more 
at 1:2–1:4 before the cultures slowed significantly in their rate of proliferation, and began to show 
signs of senescence (large, flattened morphology). During senescent crisis, cultures were not 
passaged again until regions of dividing cells or clones had emerged, and were not diluted more 
than 1:2 until cells were able to repopulate a culture dish in less than 5 days after splitting. Cultures 
that did not contain dividing cells were passaged 1:1 every 2 weeks until clones developed. When 
immortal cells emerged from the senescent cultures and expanded into clones, serial passaging was 
resumed at dilutions of at least 1:2–1:4 for several passages, followed by further passaging at 
dilutions up to 1:20. Once a culture achieved a doubling rate of ≤ 48 hr and appeared homogeneous, 
it was progressively expanded from a 6-well plate to larger flasks (25-, 75-cm
2
), frozen stocks were 
prepared and a portion of cells was pelleted for DNA extraction (≥ passage 12; 8–16 weeks).  
 
2.11. TP53 mutation analysis  
 DNA was isolated from cell pellets using the Gentra Puregene Cell Kit B (Qiagen, #158745), 
according to the manufacturer’s instructions. Human TP53 sequences (exon 4 to exon 9, including 
introns) were amplified from each sample using the human TP53-specific primers and cycling 
conditions described in Table S2. Amplification products were assessed by electrophoresis on 2% 
agarose gels (containing 0.5 µg/mL ethidium bromide) in TBE buffer. Band size and intensity were 
monitored by loading 4 µL of Gel Pilot 100 bp Plus marker (Qiagen, #239045) onto each gel. To 
remove primers and deoxynucleoside triphosphates prior to sequencing, PCR reactions (12 µL) 
were digested with 2 U exonuclease I (New England Biolabs, UK, #M0293S) and 10 U shrimp 
alkaline phosphatase (USB Products, USA, #70092Y) for 20 min at 37°C followed by an 
inactivation step at 80°C for 15 min. 
 Samples were submitted to Beckman Coulter Genomics (Takeley, UK) for Sanger dideoxy 
fluorescent sequencing using the sequencing primers indicated in Table S2. Chromas software was 
used to export the FASTA sequence from the chromatograms which were also visually inspected. 
FASTA sequences were analysed by alignment against a human TP53 reference sequence, 
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NC_000017.9 from Genbank, using the Basic Local Alignment Search Tool (BLAST) from the 
National Center for Biotechnology Information (NCBI) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
Variations (e.g. single base substitutions, deletions) were assessed using the mutation validation 
tool available at the IARC TP53 mutation database (http://www-
p53.iarc.fr/MutationValidationCriteria.asp), and could be classified as either homo-/hemi-zygous or 
heterozygous. Mutations were confirmed by sequencing DNA from an independent sample of cells 
from the same clone.  
 
2.12. Statistical analysis 
 
 All statistical analyses were carried out using SAS v. 9.3 for Windows XP (SAS Institute, 
Cary, NC).  The effects of Xpa status and chemical treatment (i.e. BaP or BPDE) on adduct 
formation were examined using ordinary least-squares 2-factor Analysis of Variance (ANOVA) 
followed by Bonferroni’s post-hoc contrasts. Homogeneity of variance across the treatment groups 
was examined using the Bartlett test. Alternatively, pair-wise comparisons employed the Student’s t 
test. The effects of Xpa status and chemical treatment (i.e. BPDE) on the frequency of TP53 mutant 
clones or TP53 mutation frequency were analysed using 2x2x2 contingency table analysis. The Chi-
square test was used to test the null hypothesis that row (i.e. chemical treatment or Xpa status) and 
column (i.e. TP53 mutant) variables are not significantly associated. Odds Ratio values were 
employed to assess the relative risk of a given outcome (e.g. TP53 mutant) for paired levels of the 
chemical treatment or Xpa genotype (e.g. Xpa-Null versus Xpa-WT or BPDE-treated versus solvent 
control).  The exact statement in Proc Freq provided exact tests and confidence limits for the 
Pearson Chi-square and Odds Ratio values. Since a small proportion of TP53 mutant clones 
contained more than one mutation, the TP53 mutation response was treated as an ordinally-scaled 
dependent variable (i.e. a multinomial response with outcome none, single or double). The effects 
of Xpa genotype and chemical treatment on mutation response were determined using ordinal 
logistic regression (i.e. cumulative logit model) in SAS Proc Catmod.  
Pair-wise statistical comparisons of mutation patterns (i.e. type of mutations) employed a 
variation on the algorithm originally published by [40]; later modified by [41]. Briefly, statistical 
comparisons of mutation patterns for two conditions (e.g. Xpa-Null versus Xpa-WT for BPDE 
treated) were assessed using the Fisher’s exact test with P values estimation determined using 
Monte Carlo simulation with 50,000 iterations. 
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3. Results 
 
3.1. Creation of Xpa-deficient Hupki mice and embryos 
 Hupki mice deficient in NER were generated by crossing the Hupki strain with transgenic mice 
harbouring an Xpa-knockout allele. The Hupki
+/+
;Xpa
-/-
 offspring were healthy and did not show 
any obvious phenotypic differences from Hupki
+/+
;Xpa
+/+
 mice within the timeframe of these 
studies (up to 6 months). Likewise, Xpa-WT and Xpa-Null HUFs were morphologically similar.  
 
3.2. BaP-induced DNA adduct formation in Xpa-WT and Xpa-Null Hupki mice 
 DNA adduct formation after treatment with BaP was initially assessed in vivo (Fig. 1, Fig. S2 
and Fig. S3). One day following a single BaP treatment at 125 mg/kg bw, DNA adduct levels were 
significantly higher in three of six tissues examined (spleen, colon and kidney) from Xpa-Null mice 
compared with their WT littermates, ranging from 1.4- to 3.7-fold (Fig. 1A). Unexpectedly, all 
Xpa-Null mice died within 2–3 days of BaP (125 mg/kg bw) treatment (Fig. 1B and Fig. S2). In the 
Xpa-WT mice, BaP-DNA adduct levels following a single treatment persisted 5 days later in all 
tissues except the small intestine where there was a 2.5-fold decrease (Fig. S2). Further, DNA 
adduct levels greatly increased in Xpa-WT animals that received BaP daily for 5 days (14-, 12-, and 
4-fold in liver, lung and small intestine, respectively) (Fig. 1B).  
 Due to the acute toxicity induced by BaP at 125 mg/kg bw in Xpa-Null mice, animals were 
treated with a 10-fold lower dose (i.e. 12.5 mg/kg bw) in a subsequent experiment (Fig. 1C and D). 
A single low dose of BaP (12.5 mg/kg bw) resulted in detectable DNA adducts in all tissues 
examined which exhibited a trend towards being higher in Xpa-Null mice compared to Xpa-WT 
mice (ranging from 1.8-fold [spleen] to 2.7-fold [small intestine]) (Fig. 1C) in line with the results 
obtained after a single administration of 125 mg/kg bw (compare to Fig 1A). Xpa-Null mice were 
able to tolerate 5 daily treatments with the lower dose of BaP. Interestingly, after 5 daily treatments, 
DNA adduct levels were about the same in Xpa-WT and Xpa-Null animals (Fig. 1D). Taken 
together, these experiments indicate that BaP-DNA adduct removal is dependent on Xpa/NER 
within 1 day of treatment, although NER fails to remove these adducts following 5 days of BaP 
exposure even in Xpa-WT mice. Further, the inability of Xpa-Null mice to repair BaP-DNA adducts 
can result in lethal toxicity if the DNA damage exceeds a certain threshold. 
 
3.3. Growth of Xpa-WT and Xpa-Null HUFs at 20% and 3% oxygen  
 Due to the previously reported inhibition of culture-induced senescence of MEFs at 3% O2, we 
sought to determine whether the growth of primary HUFs could also be enhanced and/or extended 
in 3% oxygen. Growth curves were generated over 6–9 weeks of culture in order to establish the 
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growth characteristics of both Xpa-WT and Xpa-Null HUFs in 20% and 3% oxygen (Fig. 2A and 
B).  
 In 20% O2 the primary HUF cultures (Xpa-WT and Xpa-Null) rapidly proliferated for the first 
several days in culture (Fig. 2A). After 5 days the original populations had increased approximately 
40-fold, and after 11 days the populations had increased about 200-fold. The proliferation of HUFs 
in 20% O2 markedly decreased after 11–15 days, as cells began to senesce. The cultures resumed 
proliferation after 35–45 days as immortal cells emerged. 
 The HUF cultures grew rapidly in 3% O2 for the first 11 days, at a slightly increased rate 
compared with cells grown in 20% O2, doubling every 24–30 hr (Fig. 2B). After 5 days, the original 
populations had increased by 70-fold, and after 11 days they had increased by 2100-fold. After this 
point the cultures temporarily proliferated at a reduced rate (to varying degrees) and the cells 
appeared morphologically heterogeneous. By 25 days in culture in 3% O2, cultures were again 
rapidly proliferating and were homogeneous in appearance.  
 Another set of HUF cultures was grown in 3% O2 for 1 week and then transferred to 20% O2, 
in order to determine whether cultures grown temporarily at 3% O2 would still be capable of 
senescence and immortalisation at 20% O2 (Fig. S4). Following transfer to 20% O2, the cultures 
underwent 2 population doublings in the first 3 days of culture, but then slowed and began to 
senesce by the next passage. Similarly to cells grown continuously at 20% O2, immortalised cells 
emerged in the cultures after 35–40 days. 
 
3.4.   Effect of oxygen on DNA adduct formation in HUFs treated with BaP 
 The growth curves generated in 20% and 3% O2 indicated a clear growth advantage for 
primary HUFs grown in 3% O2, at least prior to 2 weeks in culture. However, the impact of 3% 
versus 20% O2 on the metabolic activation of carcinogens (i.e. BaP) has not been previously 
examined. Primary Xpa-WT HUFs grown in 20% and 3% O2 (passage 1, ≤ 7 days in culture) were 
treated with 1 µM BaP for 24 or 48 hr to assess DNA adduct formation (Fig. 2C). Interestingly, 
DNA adduct levels were markedly higher in HUFs treated in 3% O2 than in cells treated in 20% O2. 
After 24 hr treatment, a 4-fold higher level of DNA adducts was detected in HUFs treated in 3% O2 
(513 ± 34 versus 129 ± 10 adducts per 10
8
 nt) and after 48 hr treatment DNA adduct levels were 2-
fold higher in 3% O2 (839 ± 294 versus 391 ± 27 adducts per 10
8
 nt) than in cells treated in 20% O2. 
Therefore, growing HUFs temporarily in 3% O2 not only provides a substantial increase in cells 
available for experiments, but may enhance the formation of DNA-reactive metabolites following 
treatment with environmental carcinogens. From these observations, all subsequent experiments 
were performed in 3% O2. 
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3.5.   Survival of Xpa-WT and Xpa-Null HUFs treated with BaP or its reactive intermediate 
BPDE 
 Previous studies using MEFs from Xpa-knockout mice (with WT Trp53) showed that Xpa-
deficient cells are highly sensitive to DNA damage that is normally repaired by NER, including that 
induced by BaP [20, 42, 43]. Here, we have compared Xpa-Null HUFs with Xpa-WT HUFs for 
their sensitivity to BaP and its reactive intermediate BPDE. Xpa-Null HUFs were indeed more 
sensitive to treatment with both compounds, although the difference was more pronounced after 48 
hr (Fig. 3A and B). Following treatment with 1 µM BaP, 63% of Xpa-Null cells had survived after 
24 hr (91% for Xpa-WT), but by 48 hr BaP-treated Xpa-Null cells were 23% of control (60% for 
Xpa-WT) (Fig. 3A). Upon 1 µM BPDE treatment, 41% of Xpa-Null cells had survived after 24 hr 
(59% for Xpa-WT), but this had decreased to 6% at 48 hr (47% for Xpa-WT) (Fig. 3B). 
Interestingly, surviving Xpa-Null cells treated with ≥ 0.5 µM BaP did not resume proliferation, 
whereas those treated with ≤ 0.25 µM BaP resumed proliferation within 1–2 days of treatment 
(monitored visually with a microscope for up to two weeks; data not shown). 
   
3.6.   BaP- and BPDE-induced DNA adduct formation in Xpa-WT and Xpa-Null HUFs 
 Xpa-Null HUFs were shown to be highly sensitive to treatment with BaP and BPDE. Next, the 
level of DNA adducts induced by these compounds was assessed in Xpa-Null and Xpa-WT HUFs 
(Fig. 3C and D). Cells were treated with 0.05–1.0 µM of BaP for 24 hr or 0.125–1.0 µM BPDE for 
2 hr. A concentration-dependent increase in DNA adduct formation was found after treatment with 
both compounds.  
 Interestingly, the Xpa-Null HUFs, despite being deficient in NER, accumulated similar or 
slightly lower levels of BaP-induced DNA adducts to Xpa-WT HUFs, reaching up to 370 ± 111 
adducts per 10
8
 nt at 1 µM BaP versus 513 ± 34 adducts per 10
8
 nt in Xpa-WT HUFs. On the other 
hand, DNA adduct formation following BPDE treatment was slightly higher in Xpa-Null HUFs 
than in Xpa-WT HUFs, although the difference was significant only at the highest concentration of 
BPDE (1 µM) where DNA adduct levels reached 566 ± 88 adducts per 10
8
 nt in Xpa-Null HUFs 
versus 475 ± 40 adducts per 10
8
 nt in Xpa-WT HUFs.  
 Additionally, we examined a time course of BPDE adduct formation and removal in Xpa-WT 
and Xpa-Null HUFs. Previous studies have shown that the half-life of BPDE in cells is ~12 minutes 
and peak adduct formation appears to vary from 20 min to 2 hr, perhaps depending on cell type and 
experimental design [44-46]. Here, HUFs were treated with 0.25 µM BPDE for up to 2 hr, and one 
set of cultures was further incubated in normal medium for 4 hr after BPDE was removed. Cells 
were harvested to assess DNA adduct levels at 30 min, 2 hr and 6 hr (Fig. S5). Longer incubation 
times were not included to avoid effects caused by proliferation. After 30 min incubation with 
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BPDE, Xpa-Null and Xpa-WT HUFs accumulated the same level of DNA adducts (138 ± 1 adducts 
per 10
8
 nt in both Xpa-Null and Xpa-WT HUFs). This initial DNA adduct level progressively 
declined in Xpa-WT HUFs, by 18% at 2 hr (114 ± 7 adducts per 10
8
 nt) and by 30% at 6 hr (96 ± 12 
adducts per 10
8
 nt). In Xpa-Null HUFs, however, DNA adduct levels peaked at 2 hr (161 ± 19 
adducts per 10
8
 nucleotides), and were similar at 6 hr to the levels detected at 0.5 hr (132 ± 3 
adducts per 10
8
 nt). These results demonstrate that Xpa-WT HUFs are able to repair BPDE-DNA 
adducts over time, while the repair capacity of the Xpa-Null HUFs is impaired. 
 
3.7. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null HUFs 
3.7.1. Mutation frequency 
 Primary Xpa-WT and Xpa-Null HUF cultures (102 per genotype) were exposed for 2 hr to 0.5 
µM BPDE and then serially passaged for 8–16 weeks (≥ 12 passages) in 20% O2, resulting in one 
immortalised cell line per culture. Untreated cells of each Xpa genotype (54 cultures) were 
immortalised in parallel. Mutations in the human TP53 sequence of immortalised HUF lines were 
identified by PCR amplification of exons 4–9 (along with adjacent introns) and direct dideoxy 
sequencing (Tables 1 and 2). From untreated HUF cultures, only two spontaneously immortalised 
lines of each Xpa genotype were found to contain mutated TP53 (3.7%). Treatment with BPDE 
markedly increased the frequency of TP53 mutations over that observed in untreated cultures. Of 
the 102 immortalised cell lines derived from BPDE-exposed Xpa-WT HUFs, 16 clones harboured a 
total of 20 mutations (four clones carried two mutations each), while 23 immortalised cell lines 
derived from BPDE-exposed Xpa-Null HUFs harboured a total of 29 mutations (six clones 
contained two mutations each). Statistical data analyses initially examined the effect of BPDE 
treatment on the frequency of TP53 mutant clones, and confirmed a statistically significant effect 
for both Xpa-WT cells (i.e. Chi-squared = 5.0, P < 0.04) and Xpa-Null cells (i.e. Chi-squared = 9.3, 
P < 0.003). Similarly, the analyses showed a significant effect of BPDE treatment on TP53 
mutation frequency for Xpa-WT cells (i.e. Chi-squared = 4.1, P < 0.05) as well as Xpa-Null cells 
(i.e. Chi-squared = 7.1, P < 0.008). Furthermore, these data suggest a trend for an increased 
frequency of TP53 mutagenesis in BPDE-exposed Xpa-Null HUFs (22.5%) compared with Xpa-
WT HUFs (15.7%) that was confirmed by statistical analyses. More specifically, Odds Ratio values 
confirmed that Xpa-Null cells are more susceptible to the effects of BPDE treatment (i.e. OR = 7.6, 
95% confidence interval = 1.7 to 33.5) as compared with Xpa-WT cells (i.e. OR = 4.8, 95% 
confidence interval = 1.1 to 21.9). However, the increase in the relative risk of TP53 mutation 
between Xpa-Null and Xpa-WT HUFs is not statistically significant due to the relatively small 
number of mutants obtained and the consequently low statistical power. Indeed, separate statistical 
analysis that examined the impact of Xpa status on TP53 mutation frequency for BPDE treated cells 
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only failed to detect a significant effect (i.e. Chi-squared = 1.9, P = 0.19, OR = 1.6 with 95% 
confidence interval = 0.83 to 3.0). 
 
3.7.2. Mutation pattern 
 Most mutations induced by BPDE occurred at G:C base pairs (90% Xpa-WT; 83% Xpa-Null), 
predominantly consisting of single base substitutions (Table 2 and Fig. 5). The most frequent 
mutation type was a G:C>T:A transversion (40% Xpa-WT; 31% Xpa-Null), the signature mutation 
of BaP/BPDE, followed by G:C>C:G transversions (25% Xpa-WT; 21% Xpa-Null), and G:C>A:T 
transitions (20% Xpa-WT; 17% Xpa-Null). Single or tandem deletions of guanines, leading to a 
frameshift, were also observed but were more frequent in Xpa-Null clones (5% Xpa-WT; 14% Xpa-
Null). Approximately half of the mutations at G:C base pairs occurred at CpG sites (56% Xpa-WT; 
46% Xpa-Null). Out of 33 CpG sites between exons 4–9 in TP53, 11 were mutated by BPDE, most 
commonly resulting in G:C>C:G or G:C>T:A transversions. Of the four mutations found in 
untreated control cultures, one was a G:C>C:G transversion and three were A:T>C:G transversions. 
The A:T>C:G mutation type did not occur in BPDE-treated Xpa-WT HUFs but was found in three 
BPDE-treated Xpa-Null clones (XN-BP-278, -299, -300).  
 
3.7.3. Strand bias 
 It has been shown previously that DNA damage induced by BPDE is repaired more rapidly if it 
occurs on the transcribed strand of TP53 compared with the non-transcribed strand [47, 48]. This is 
thought to explain the strand bias of G to T mutations in TP53 found in lung tumours of tobacco 
smokers, where mutations are preferentially found on the non-transcribed strand [49]. In contrast, in 
TC-NER-deficient cells mutations are biased in favour of the transcribed strand [50, 51]. Indeed, 
here we found an increased number of BPDE-induced mutations on the transcribed strand in Xpa-
Null HUFs (38%) relative to Xpa-WT HUFs (10%) (Table 1 and Fig. 4). Statistical analysis to 
examine the influence of Xpa status on the transcribed and non-transcribed strand BPDE-induced 
TP53 mutation frequencies, respectively, showed a statistically significant effect for the former, but 
not the latter. More specifically, Xpa status had a significant effect on the frequency of BPDE-
induced mutations on the transcribed strand (i.e. Chi-squared = 6.5, P < 0.02). Moreover, the Odds 
Ratio confirmed a 6-fold increase in the average likelihood of BPDE-induced transcribed strand 
mutations for Xpa-Null cells compared to Xpa-WT cells (i.e. OR = 6.0, 95% confidence interval = 
1.3 to 27.8). No such effect of Xpa status was observed for BPDE-induced TP53 mutations on the 
non-transcribed strand (i.e. Chi-squared = 0.05, P = 0.86). All mutation types detected on the non-
transcribed strand of Xpa-Null clones were also found on the transcribed strand, with the exception 
of A:T>T:A. 
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3.7.4. Effect of mutations on p53 protein function 
 The majority of BPDE-induced TP53 mutations were missense (37/49). Additionally, three 
nonsense (R65X, W91X, E171X), three silent (P34P, V157V, L188L), one splice (acceptor site, 
intron 6) and five frameshift (codons 158, 189, 267, 330) mutations were induced, most of which 
occurred in Xpa-Null clones. All of the silent mutations occurred in clones that harboured a second 
mutation. Most of the missense mutations found in the immortalised HUF clones could be classified 
as ‘non-functional’ (NF), or defective in transactivation activity, as determined by a comprehensive 
yeast functional study [52]. This indicates, as shown previously, that loss of transactivation activity 
is an important aspect of senescence bypass by p53 inactivation [53]. However, eight missense 
mutations were classified as ‘partially functional’ (PF) or functional (F), whereby these p53 mutants 
retained some or all of their transactivation activity. Notably, all but one (R196G) of the PF/F 
mutants occurred in clones that also contained a second mutation, suggesting that partial loss of p53 
transactivation function is not sufficient for senescence bypass. 
 
3.7.5. Influence of sequence context 
 We also examined how sequence context and the presence of methylated CpG sites influenced 
the pattern of G:C base pair mutations induced by BPDE. In Table S3 mutations of each type were 
sorted by the bases 5’ and 3’ to the mutated base. For G:C>A:T transitions, mutations occurred at 
CpG sites (2/9), at GG pairs (7/9; two of which were also CpG sites), or at G bases with a 5’ or 3’ T 
(4/9; two of which were also GG pairs). For G:C>C:G transversions, mutations occurred at CpG 
sites (7/11) or at GG pairs (7/11; three of which were also CpG sites). For G:C>T:A transversions, 
most mutations occurred at CpG sites (9/17), and the remaining mutations arose at GG pairs (6/17; 
one also being a CpG site) or in a 5’T-G-T3’ context (3/17). Similarly, deletions at G:C base pairs 
occurred either at CpG sites (3/5) or at GG pairs. In the case of mutations occurring at GG pairs, the 
second G was 5’ or 3’ to the mutated base. 
 
3.7.6 Codon distribution and comparison to human cancer mutation spectra 
 A total of 46 unique BPDE-induced mutations were detected in the sequenced exons (4–9), 
occurring in 38 codons overall. Three codons (158, 196, 273) were mutated in both Xpa-WT and 
Xpa-Null clones, but unique mutations were induced in each case. Mutations were found in codons 
for two key residues that make direct contact with the DNA (R248, R273), three that support the 
structure of the DNA binding surface (G245, R249, R282) and one that is important for 
coordinating Zn(2+) binding (C242). 
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 The mutations identified in BPDE-exposed HUF clones were compared with TP53 mutations 
found in human cancer across all tumour types, as well as specifically in lung cancer from smokers 
and non-smokers, using the IARC TP53 mutation database, version R17 (Fig. 5). All but five of the 
46 TP53 mutations found in BPDE-exposed HUFs have been detected in at least one human tumour 
(Table S4). Mutations that were infrequently or not found in human tumours included silent 
mutations, frameshifts, and mutations that resulted in a partially functional mutant p53 protein. Of 
the six hotspots most frequently mutated across all cancer types (R175, G245, R248, R249, R273, 
and R282), mutations were induced by BPDE at each, with the exception of R175. Further, BPDE 
also targeted two lung cancer-specific hotspots, codons V157 and R158. All of these hotspots, with 
the exception of codon 249, contain CpG sites. 
 At codon 157 (GTC), BPDE induced one G:C>T:A mutation at the 1
st
 position and one 
G:C>A:T mutation at the 3
rd
 position. At codon 158 (CGC), BPDE induced a G:C base pair 
deletion at the 1
st
 position and two G:C>T:A mutations at the 2
nd
 position. Codon 157 and 158 are 
more frequently targeted in smokers’ lung cancer compared with cancer overall, with G:C>T:A 
transversions predominating (codon 157: 24/30; codon 158: 32/44). In cancer overall, G:C>T:A 
transversions are also the most common mutation type at codon 157 (210/313), but are less frequent 
at codon 158 (102/326), where G:C>A:T transitions at the second position are more common 
(113/326). No mutations at codons 157 or 158 have ever been detected in spontaneously 
immortalised HUFs (Table S5). 
 The most frequently mutated TP53 codons in cancer overall and in smokers’ lung cancer are 
248 and 273 (Fig. 5). Likewise, these two codons were hotspots for BPDE-induced mutations in the 
current HIMA. In cancer overall and nonsmokers’ lung cancer, the most frequent mutation type at 
codon 248 (CGG) is G:C>A:T (~90%), and indeed two of the mutations induced by BPDE were 
G:C>A:T transitions at the 2
nd
 position. Additionally, one G:C>T:A mutation at the 2
nd
 position was 
detected in the BPDE-treated HUFs. G:C>T:A transversions at the 2
nd
 position in codon 248 are 
much more frequent in smokers’ lung cancer (23/56) compared with all cancer (121/1880). Notably, 
mutation at codon 248 has not been detected in untreated, spontaneously immortalised HUFs 
(Table S5). With regards to codon 273 (CGT), BPDE-induced mutations included one G:C>T:A 
transversion at the first position, one G:C>C:G transversion at each of the 1
st
 and 2
nd
 positions, and 
two G:C>T:A mutations at the 2
nd
 position. The most common mutation type found in human 
cancer at codon 273 is G:C>A:T (~90%); G:C>T:A transversions at the 2
nd
 position are much more 
frequent in smokers’ lung cancer (30/62). G:C>C:G mutations at codon 273 occur in 1-2% of 
cancer overall and 3-5% of smoker’s lung cancer.  
 
3.7.7 Comparison to mutations induced in previous HIMAs 
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 BPDE-induced TP53 mutations were compared further with mutations detected in previous 
HIMAs (Table  S5), including HUFs treated with BaP, 3-NBA, AAI, UV and MNNG and untreated 
controls. Seven codons mutated by BPDE were also mutated in cells treated with BaP (135, 157, 
158, 224, 248, 273, 282), and six identical mutations were induced by both compounds. Codons 157 
and 224 were not mutated in HIMAs using other compounds. One mutation at codon 158 was 
induced by AAI, one mutation at codon 248 was induced by UV, and codon 273 was targeted once 
each by 3-NBA and AAI.   
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4. Discussion 
 We have generated an NER-deficient Hupki model by crossing the Hupki mouse with an Xpa-
deficient mouse. We hypothesised that Xpa-deficiency would increase the sensitivity of the Hupki 
model to DNA damage normally repaired by NER and thereby increase the frequency of 
carcinogen-induced TP53 mutations in immortalised HUFs. Xpa-WT and Xpa-Null mice and HUFs 
were treated with the ubiquitous environmental carcinogen BaP, or its reactive metabolite BPDE, 
which form DNA adducts (BPDE-N
2
-dG) that have been shown to be repaired by the NER 
pathway. We found that Xpa-Null Hupki mice and HUFs were more sensitive than their Xpa-WT 
counterparts to the DNA damage induced by BaP or BPDE, exhibiting pronounced mortality at the 
highest doses tested. Further, we observed a bias for BPDE-induced mutations on the transcribed 
strand of TP53 in immortal clones derived from Xpa-Null HUFs, although TP53 mutation 
frequency overall was not significantly increased in Xpa-Null HUFs compared to Xpa-WT HUFs. 
 Although BaP- and BPDE-induced DNA adduct levels were generally similar between Xpa-
WT and Xpa-Null HUFs, Xpa-Null cells were less able to survive the DNA damage. This suggests 
that the sensitivity of Xpa-Null cells was not due to retention of more DNA adducts. The sensitivity 
of Xpa-Null HUFs to BaP and BPDE is more likely caused by the blockage of RNAPII by BPDE-
N
2
-dG adducts in actively transcribed genes. The persistence of DNA lesions on the transcribed 
strand of active genes in TC-NER-deficient cells is a strong trigger for apoptosis induction [54]. It 
has been observed that Xpa-Null cells, deficient in both GG- and TC-NER, undergo apoptosis after 
DNA damage induced by carcinogens such as UV or BaP, whereas Xpc-Null cells, deficient only in 
GG-NER, do not, although this may be cell-type specific [55]. TC-NER-deficient cells are unable to 
repair RNAPII-blocking lesions; subsequent induction of apoptosis appears to occur during 
replication, possibly due to collision of DNA replication forks with stalled transcription complexes 
during S phase [56].  
 Xpa-Null Hupki mice were also highly sensitive to treatment with BaP; while treatment was 
well tolerated by Xpa-WT Hupki mice, Xpa-Null mice died within 2–3 days of receiving the 
highest dose tested (i.e. 125 mg/kg bw BaP). This sensitivity to genotoxins has been shown 
previously for Xpa-Null mice with WT Trp53 after exposure to UV, 7,12-
dimethylbenz[a]anthracene (DMBA), BaP and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP) [18, 57]. As discussed above for HUFs, the sensitivity of Xpa-Null mice to these 
carcinogens is likely due to TC-NER deficiency and blockage of RNAPII by unrepaired DNA 
adducts. Xpc-Null mice, deficient only in GG-NER, do not share the same sensitivity [58]. One day 
following a single treatment with BaP, several tissues analysed from Xpa-Null Hupki mice had a 
higher level of BPDE-N
2
-dG adducts compared with Xpa-WT mice. When the animals were treated 
with 5 daily doses of BaP (12.5 mg/kg bw), however, similar DNA adduct levels were detected in 
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Xpa-WT and Xpa-Null mice. This suggests that GG-NER is activated initially following BaP 
treatment in Xpa-WT mice, but is unable to deal with continuing damage. Interestingly, when BaP 
was previously tested in Xpa-Null and Xpa-WT mice with WT Tp53 (3 doses of 13 mg/kg bw per 
week for 13 weeks), 9 weeks of treatment were required before DNA adduct levels in Xpa-Null 
mice surpassed those of Xpa-WT mice [22]; in that experiment DNA adduct formation was not 
assessed following a single treatment. Our results and those of others [22, 59] suggest that GG-NER 
kinetics of BPDE-N
2
-dG adducts in NER-proficient mice is dose- and time-dependent. It is apparent 
that further investigations are required to explain these observations. 
 In addition to increased sensitivity to BPDE-N
2
-dG adducts, Xpa-Null HUFs also exhibited 
enhanced BPDE-induced mutagenesis on the transcribed strand of TP53 compared with Xpa-WT 
HUFs following BPDE treatment. These data further suggest that Xpa-Null HUFs are unable to 
repair BPDE-N
2
-dG adducts on the transcribed strand; adducts that do not induce apoptosis may be 
converted to mutations. While the number of immortal Xpa-WT and Xpa-Null clones harbouring 
TP53 mutations on the non-transcribed strand was nearly the same, 5.5-fold more Xpa-Null clones 
contained mutations on the transcribed strand compared to Xpa-WT clones. Further, the number of 
additional mutations on the transcribed strand induced by BPDE in Xpa-Null HUFs was equal to 
the overall increase in TP53 mutations in Xpa-Null HUFs compared to Xpa-WT cells (see Table 1). 
This, and the accompanying statistical analyses, suggests that the increase in BPDE-induced TP53-
mutagenesis in Xpa-Null HUFs compared to Xpa-WT cells can be primarily be accounted for by 
the inability of Xpa-Null HUFs to repair damage on the transcribed strand. 
 It is unclear why Xpa-deficiency did not also increase TP53 mutagenesis on the non-
transcribed strand. It is known that repair of BPDE-DNA adducts is slower on the non-transcribed 
strand compared to the transcribed strand in the TP53 gene of normal human fibroblasts, creating a 
bias of mutations on the non-transcribed strand in NER-proficient cells [47]. Despite the relative 
inefficiency of GG-NER compared to TC-NER, BPDE-DNA adduct removal from the bulk of the 
genome has been shown, to varying extents, in multiple studies. The amount of removal within 8 hr 
of BPDE exposure ranged between 5–60% in normal human fibroblasts [60], to 50% in V79-XEM2 
cells [45], to 75% removal in A549 lung carcinoma cells [44]. In the current study, we found that 
Xpa-WT HUFs removed 30% of BPDE-N
2
-dG adducts within 6 hr of treatment. It is not known 
what percentage of BPDE-N
2
-dG adducts may have persisted in the HUF genomes beyond this 
time-point.  
 Few studies have compared BaP/BPDE-induced mutagenesis in NER-proficient and NER-
deficient cells. Xpa-Null mouse embryonic stem cells treated with BaP exhibited a higher rate of 
Hprt mutations than their WT counterparts, although the Xpa-Null cells also had a higher rate of 
spontaneous mutagenesis [43]. Further, more Hprt mutations were induced by BPDE in an NER-
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defective Chinese hamster ovary cell line (UV5) relative to a WT line (AA8) [45]. On the other 
hand, in vivo, similar mutation frequencies at a lacZ reporter gene were detected in the liver and 
lung of BaP-treated Xpa-Null and Xpa-WT mice; lacZ mutation frequencies did increase in the 
spleens of Xpa-Null mice, but only after 13 weeks of BaP treatment [22]. Thus, the impact of NER-
deficiency on mutagenesis resulting from BPDE-N
2
-dG adducts may be cell-type specific or 
dependent on the target gene of interest and whether or not the gene is subject to TC-NER (e.g. lacZ 
is not transcribed by mammalian cells). 
 In agreement with previous studies, the majority of BPDE-induced TP53 mutations occurred at 
G:C base pairs in both Xpa-WT and Xpa-Null HUFs, with G:C>T:A transversions being the 
predominant mutation type [14, 61, 62]. A high percentage (46–56%) of the mutations at G:C base 
pairs occurred at CpG sites; G:C>C:G and G:C>T:A transversions were more common at these sites 
than G:C>A:T transitions. Further, we found that BPDE induced mutations at several sites that are 
hotspots for mutation in cancer overall (codons 245, 248, 249, 273, 282), or smokers’ lung cancer 
specifically (codons 157 and 158, in addition to those listed for cancer overall). Codons 157, 158 
and 273 were also mutated in prior HIMAs with BaP-treated HUFs [14]. 
 The pattern and spectrum of TP53 mutagenesis can be influenced by a number of factors.  In 
previous studies DNA adduct formation by BPDE was enhanced at methylated CpG sites in TP53 
hotspot codons 157, 158, 245, 248, and 273 on the non-transcribed strand [63, 64]; the precise 
mechanism underlying this phenomenon is not yet understood. It has been proposed that the methyl 
group of 5-methylcytosine allows increased intercalation of BPDE at methylated CpG sites and that 
this increase in BPDE intercalative binding subsequently results in increased covalent interaction 
[65, 66]. Others have suggested that the methylation of cytosine enhances the nucleophilicity of the 
exocyclic amino group of the base paired guanine (electronic effect) [67]. All of the CpG sites in 
Hupki TP53 are methylated [68]. Interestingly, codon 179 (CAT), which is a mutation hotspot in 
smokers’ lung cancer but does not contain a CpG site or a G on the non-transcribed strand, was not 
mutated by BPDE in our study and was not targeted by BPDE in normal human bronchial epithelial 
(NHBE) cells [69]. On the other hand, codon 267 (CGG), which is infrequently mutated in lung 
cancer but does harbour a CpG site, was mutated by BPDE in two HUF clones and exhibited 
pronounced BPDE-DNA adduct formation in NHBE cells [69]. Our data provide additional support 
for the idea that certain TP53 mutation hotspots (i.e. codons 157, 158, 248, 273) act as selective 
BPDE binding sites.  
 Additional factors such as sequence context, efficiency of lesion repair (as discussed above), 
and fidelity of translesion synthesis polymerases also play important roles in TP53 mutagenesis. We 
found that a common context for BPDE-induced single base substitutions or deletions at G:C base 
pairs was GG dinucleotide sequences; mutation hotspots for BPDE-N
2
-dG adducts have previously 
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been found in such sequences [70, 71]. Sequence context likely influences adduct conformation 
which may result in different sequence-dependent removal rates of the lesion and also control 
mutagenic specificity. 
 Furthermore, the TP53 mutations ultimately observed in human cancers are strongly influenced 
by functional selection for mutants that have a deleterious impact on the normal function of p53 or 
that acquire gain-of-function properties [6]. For example, many mutation hotspots occur at codons 
for amino acids that are essential for DNA contact (248, 273) or structure of the DNA binding 
domain (175, 245, 249, 282); mutations at these sites create a mutant protein that lacks the ability to 
transactivate the normal suite of p53 target genes. With the exception of codon 175, all of these 
hotspots were mutated by BPDE in our study. Further, most of the missense TP53 mutations 
detected in our study were classified as non-functional and, with one exception, the mutations that 
retained some functionality occurred only in clones that also harboured a non-functional mutation. 
Taken together, the pattern and spectrum of mutations generated in this study indicate that similar 
factors influence TP53 mutagenesis in the HUF immortalisation assay and human cancer, further 
supporting the strength of this model for assessing the effects of carcinogens on this tumour 
suppressor gene. 
 We also showed that the replicative capacity of primary HUFs could be extended by culturing 
the cells at 3% O2. After 11 days of culture, the population increase of HUFs grown at 3% O2 was 
10-fold higher than that of HUFs grown at 20% O2. The enhanced growth permitted by temporary 
culture in 3% O2 provides a substantial increase in cells available for further experiments. To select 
for TP53-mutated cells, HUFs must eventually be transferred to 20% O2, where the ability of cells 
to bypass senescence serves as the selection pressure for mutants. Importantly, we found that 
untreated HUFs grown at 3% O2 for one week were still able to senesce when transferred to 20% 
O2, and immortal variants that bypassed senescence developed in a similar timeframe to cells 
maintained at 20% O2. Parrinello et al. found that MEFs cultured at 3% O2 for more than 15 
population doublings (≥ 30 days) lost their propensity to senesce at 20% O2, which they speculated 
may be due to a mutagenic event or adaptive response [37]. It may therefore only be beneficial to 
culture HUFs for 1–2 weeks at 3% O2.  
 In addition to a clear growth advantage, we found that HUFs accumulated a higher level (2–4 
fold) of DNA adducts at 3% O2 relative to 20% O2 following treatment with BaP. We did not 
determine the mechanism for this in our study, but future work could examine the 
expression/activity of enzymes required for BaP activation (i.e. Cyp1a1 and Cyp1b1) at 3% O2 and 
20% O2. Recent work by van Schooten et al., using the human lung carcinoma cell line A549 
treated with BaP, has shown that the level of DNA adducts and the gene expression of CYP1A1 and 
CYP1B1 was increased under hypoxic conditions (0.2% O2), while gene expression of UDP-
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glucuronosyltransferase detoxifying enzymes UGT1A6 and UGT2B7 decreased [72]. The authors 
concluded that the balance of metabolism of BaP shifts towards activation instead of detoxification 
under low oxygen conditions. These results corroborate our findings that altered oxygen levels can 
influence the metabolic activation of compounds such as BaP.  
 Although we were unable to detect a significant increase in BPDE-induced TP53 mutations 
overall in Xpa-Null HUFs compared to Xpa-WT HUFs, perhaps a divergence in mutation frequency 
would be evident at the genome-wide level. Less than 25% of HUF clones were immortalised by 
TP53 mutation, thus other genes are clearly involved in senescence bypass by HUFs and could also 
be targeted by BPDE [53]. Recently, exome sequencing of DNA from HUFs treated with various 
mutagens (e.g. BaP and AAI) was used to extract genome-wide mutational signatures of mutagen 
exposure [73]. This study demonstrates that a single mutagen-treated immortal HUF clone harbours 
hundreds of single base substitutions at the exome level, likely consisting of both immortalisation 
driver mutations and passenger mutations. Therefore, whole-genome sequence analysis of BPDE-
treated Xpa-WT and Xpa-Null clones may allow differences in mutation frequency in the context of 
the genome to be detected that are not observed in an assay for a single gene. Furthermore, beyond 
simply increasing mutation frequencies, Xpa-Null HUFs may be useful in the future to enhance our 
understanding of the role of NER in shaping carcinogen-induced mutagenesis of both TP53 and the 
genome. 
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Table 1. Summary of TP53 mutation frequency and patterns in immortalised clones of Xpa-
WT and Xpa-Null HUFs treated with BPDE and from spontaneously immortalised controls.  
 
BPDE Xpa-WT Xpa-Null control Xpa-WT Xpa-Null
Total BPDE-treated HUF cultures (#) 102 102 Total 0.1% DMSO-treated HUF cultures (#) 54 54
TP53 -mutant immortalised clones (#) 16 23 TP53 -mutant immortalised clones (#) 2 2
Total TP53  mutations detected (#) 20 29 Total TP53  mutations detected (#) 2 2
Frequency of TP53 -mutant clones 15.7% (16/102) 22.5% (23/102) Frequency of TP53 -mutant clones 3.7% (2/54) 3.7% (2/54)
Mutations on the transcribed strand 10% (2/20) 38% (11/29) Mutations on the transcribed strand 50% (1/2) 100% (2/2)
TP53 mutation pattern TP53 mutation pattern
G to A 20% (4/20) 17% (5/29) G to A 0% (0/2) 0% (0/2)
G to C 25% (5/20) 21% (6/29) G to C 50% (1/2) 0% (0/2)
G to T 40% (8/20) 31% (9/29) G to T 0% (0/2) 0% (0/2)
A to C 0% (0/20) 10% (3/29) A to C 50% (1/2) 100% (2/2)
A to G 5% (1/20) 0% (0/29) A to G 0% (0/2) 0% (0/2)
A to T 5% (1/20) 7% (2/29) A to T 0% (0/2) 0% (0/2)
del. G/GG 5% (1/20) 14% (4/29) del. G/GG 0% (0/2) 0% (0/2)
TP53 mutation pattern at CpG sites TP53 mutation pattern at CpG sites
Total G mutations at CpG 56% (10/18) 46% (11/24) Total G mutations at CpG 0% (0/1) 0% (0/0)
G to A at CpG 50% (2/4) 0% (0/5) G to A at CpG 0% (0/0) 0% (0/0)
G to C at CpG 40% (2/5) 83% (5/6) G to C at CpG 0% (0/1) 0% (0/0)
G to T at CpG 63% (5/8) 44% (4/9) G to T at CpG 0% (0/0) 0% (0/0)
del. G/GG at CpG 100% (1/1) 50% (2/4) del. G/GG at CpG 0% (0/0) 0% (0/0)  
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Table 2. TP53 mutations in immortalised clones of Xpa-WT and Xpa-Null HUFs treated with 
BPDE and from spontaneously immortalised controls.  SA = splice acceptor site; CpG indicates the 
presence of a mutation at a methylated CpG site; NTS = non-transcribed strand; TS = transcribed strand. 
Xpa 
status Clone ID* Codon # Exon
Mutation 
type Strand
WT 
codon
MUT 
codon
Coding 
change CpG Zygosity
Contact (C), 
Structure (S), 
Zinc (Z)
Activity 
(Kato) **
TP53 -mutated immortalised clones from HUFs treated with 0.5 µM BPDE
WT XW-BP-91 91 4 G:C > A:T NTS TGG TGA W91stop homo-/hemi- NA
WT XW-BP-10 132 5 A:T > T:A NTS AAG ATG R132M homo-/hemi- NF
WT XW-BP-50 143 5 G:C > A:T NTS GTG ATG V143M hetero- NF
WT XW-BP-83 154 5 G:C > T:A NTS GGC GTC G154V hetero- NF
WT XW-BP-73 158 5 del. G TS CGC _GC frameshift CpG homo-/hemi- NA
WT XW-BP-26 181 5 G:C > C:G NTS CGC CCC R181P CpG hetero- NF
WT XW-BP-17 195 6 G:C > C:G TS ATC ATG I195M homo-/hemi- PF
WT XW-BP-17 196 6 G:C > T:A NTS CGA CTA R196L CpG homo-/hemi- PF
WT XW-BP-2 203 6 G:C > T:A NTS GTG TTG V203L hetero- PF
WT XW-BP-50 213 6 G:C > T:A NTS CGA CTA R213L CpG hetero- NF
WT XW-BP-83 224 6 G:C > C:G NTS GAG GAC E224D hetero- F
WT XW-BP-42 245 7 G:C > C:G NTS GGC CGC G245R CpG hetero- S NF
WT XW-BP-16, -55 248 7 G:C > A:T NTS CGG CAG R248Q CpG homo-/hemi- C NF
WT XW-BP-95 248 7 G:C > T:A NTS CGG CTG R248L CpG hetero- C NF
WT XW-BP-2 249 7 G:C > C:G NTS AGG AGC R249S hetero- S NF
WT XW-BP-6, -63 273 8 G:C > T:A NTS CGT CTT R273L CpG homo-/hemi- C NF
WT XW-BP-9 275 8 G:C > T:A NTS TGT TTT C275F homo-/hemi- NF
WT XW-BP-38 286 8 A:T > G:C NTS GAA GGA E286G hetero- NF
Null XN-BP-229 34 4 G:C > T:A TS CCC CCA (silent) P34P hetero- NA
Null XN-BP-292 65 4 A:T > T:A NTS AGA TGA R65stop homo-/hemi- NA
Null XN-BP-201 110 4 G:C > C:G NTS CGT CCT R110P CpG hetero- NF
Null XN-BP-294 127 5 G:C > T:A TS TCC TAC S127Y homo-/hemi- NF
Null XN-BP-300 131 5 A:T > C:G NTS AAC ACC N131T hetero- PF
Null XN-BP-300 135 5 G:C > C:G TS TGC TGG C135W hetero- PF
Null XN-BP-204 155 5 G:C > A:T TS ACC ATC T155I hetero- NF
Null XN-BP-225 157 5 G:C > A:T TS GTC GTT (silent) V157V homo-/hemi- NA
Null XN-BP-268 157 5 G:C > T:A NTS GTC TTC V157F CpG homo-/hemi- NF
Null XN-BP-225, -228 158 5 G:C > T:A NTS CGC CTC R158L CpG homo-/hemi- NF
Null XN-BP-238 171 5 G:C > T:A NTS GAG TAG E171stop hetero- NA
Null XN-BP-206 188 6 G:C > T:A NTS CTG CTT (silent) L188L homo-/hemi- NA
Null XN-BP-206 189 6 del. G NTS GCC _CC frameshift homo-/hemi- NA
Null XN-BP-273 196 6 G:C > C:G TS CGA GGA R196G CpG homo-/hemi- PF
Null XN-BP-278 211 6 A:T > C:G NTS ACT CCT T211P homo-/hemi- NF
Null XN-BP-265 242 7 G:C > A:T NTS TGC TAC C242Y homo-/hemi- Z NF
Null XN-BP-229 253 7 A:T > T:A NTS ACC TCC T253S hetero- PF
Null XN-BP-299 265 8 A:T > C:G TS CTG CGG L265R hetero- NF
Null XN-BP-296 267 8 del. G NTS CGG C_G frameshift CpG homo-/hemi- NA
Null XN-BP-257 267 8 del. GG NTS CGG C__ frameshift CpG homo-/hemi- NA
Null XN-BP-210 272 8 G:C > A:T NTS GTG ATG V272M hetero- NF
Null XN-BP-237 273 8 G:C > C:G TS CGT GGT R273G CpG homo-/hemi- C NF
Null XN-BP-274 273 8 G:C > C:G NTS CGT CCT R273P CpG homo-/hemi- C NF
Null XN-BP-251 273 8 G:C > T:A TS CGT AGT R273S CpG hetero- C NF
Null XN-BP-254 274 8 G:C > T:A NTS GTT TTT V274F homo-/hemi- NF
Null XN-BP-238 282 8 G:C > C:G TS CGG GGG R282G CpG hetero- S NF
Null XN-BP-255 330 9 del. G TS CTT _TT frameshift hetero- NA
Null XN-BP-204 in. 6 (SA) G:C > A:T NTS splice hetero- NA
TP53 -mutated spontaneously immortalised clones from control HUFs (treated with 0.1% DMSO)
WT XW-C-115 138 5 G:C > C:G NTS GCC CCC A138P homo-/hemi- NF
WT XW-C-137 173 5 A:T > C:G TS GTG GGG V173G homo-/hemi- NF
Null XN-C-325 113 4 A:T > C:G TS TTC GTC F113V homo-/hemi- NF
Null XN-C-338 113 4 A:T > C:G TS TTC GTC F113V hetero- NF
* XW = Xpa-WT; XN = Xpa-Null; BP = BPDE-treated; C = control
** The overall transactivation activity of the mutant in a yeast functional assay published by Kato et al. [50]. (NF = non-functional, PF = partially functional, F
= functional, NA = not assessed)
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Legends to Figures 
Figure 1. DNA adduct formation in Xpa-WT and Xpa-Null Hupki mice treated with BaP. 
Mice were treated with BaP (125 or 12.5 mg/kg bw) as indicated; (A) and (C) were treated once, 
(B) and (D) were treated once a day for 5 days. DNA adduct levels in different tissues were 
assessed by 
32
P-postlabelling. Values represent means ± SD from 3 animals, and each DNA sample 
was measured by two independent 
32
P-postlabelling analyses. ND = not detected; † = not 
determined due to death of Xpa-Null animals. See Fig. S3 for representative autoradiograms 
showing the adduct profiles in the different tissues examined. Statistical analysis, comparing adduct 
levels in tissues from Xpa-WT and Xpa-Null mice, was performed using the Student’s t-test; * P < 
0.05, ** P < 0.01, *** P < 0.001. 
Figure 2. Growth and BaP-induced DNA adduct formation in HUFs cultured at 20% or 3% 
O2. (A) and (B): Xpa-WT or Xpa-Null HUFs (2.5  10
5 
cells/ 25-cm
2
 flask) were cultured for up to 
50 days in 20% O2 (A) or 3% O2 (B). Cells were counted every 3–4 days, diluted and reseeded to 
determine the cumulative population doublings over time. (C): Xpa-WT HUFs cultured at 20% or 
3% O2 were treated for 24 or 48 hr with 1 µM BaP. DNA adduct levels were assessed by 
32
P-
postlabelling. Values represent means ± SD of two biological replicates where each DNA sample 
was measured by two independent 
32
P-postlabelling analyses.  
Figure 3. Survival of Xpa-WT and Xpa-Null HUFs and DNA adduct formation following 
treatment with BaP or BPDE. (A) and (B) Cells were treated with the indicated doses of BaP (24 
or 48 hr) or BPDE (2 hr); survival was measured at 24 or 48 hr following initiation of treatment 
using a crystal violet staining assay. Cells treated with 0.1% DMSO served as solvent control. Mean 
values are shown as % of control ± SD of 5 replicate wells. The data are representative of at least 
three independent experiments (variation ≤ 15%). (C) and (D) Cells were treated with the indicated 
doses of BaP (24 hr) or BPDE (2 hr). DNA adduct levels were assessed by 
32
P-postlabelling. Values 
represent means ± SD of two biological replicates where each DNA sample was measured by two 
independent 
32
P-postlabelling analyses. Statistical analysis, comparing DNA adduct levels in Xpa-
WT and Xpa-Null HUFs, was performed by 2-factor ANOVA followed by Bonferroni’s post-hoc 
contrasts; * P < 0.05. Inserts: Autoradiographic profiles of DNA adducts obtained in HUFs treated 
with BaP, as indicated; the origins, in the bottom left-hand corner, were cut off before exposure; 
arrow shows 10-(deoxyguanosin-N
2
-yl)-7,8,9-trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene 
(BPDE-N
2
-dG). 
Figure 4. The pattern and strand bias of TP53 mutations in immortalised clones of Xpa-WT 
and Xpa-Null HUFs treated with BPDE. (A) The percentage of each type of single base 
substitution or deletion is shown. (B) The number of each type of single base substitution or 
deletion occurring on the non-transcribed strand (NTS) or transcribed strand (TS) is shown. 
Figure 5. The codon distribution of TP53 mutations induced by BPDE in Xpa-WT and Xpa-
Null HUFs compared with the spectrum found in human tumours. Shown are (A) the number 
of mutations at each codon (within exons 4–9) in the TP53 gene induced by BPDE in HUFs 
compared with the frequency of mutation at each codon in (B) lung cancer of smokers (exclusions: 
radon, asbestos, mustard gas, and coal [74, 75]), (C) lung cancer of non- and passive-smokers 
(exclusions: radon, asbestos, mustard gas, and coal [74, 75]) and (D) cancer overall. Reference for 
33 
 
human cancer mutation codon distribution: IARC TP53 Mutation Database, R17 (November 2013). 
Mutation hotspots are indicated in grey. 
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Supplementary Tables and Figures 
40 
 
Table S1. Primer sequences and PCR conditions for genotyping Hupki, mouse Trp53, WT Xpa 
and Xpa-knockout alleles. 
 
Allele Primer Name Primer sequence Primer details
IMR1732 5' GCC TCA TCT TGG GCC TGT GTT ATC TCC 3' Forward primer for Hupki  allele
IMR1733 5' GGC CAG TGT GCA GGG TGG CAA GTG GCT C 3' Reverse primer for Hupki  allele
IMR1734 5' ACT CCA TGG CCC CTG TCA TC 3' Forward primer for wild-type mouse Trp53  allele
IMR1735 5' AGG TCA CAC GAA AGA CAA CT 3' Reverse primer for wild-type mouse Trp53  allele
XP26 5' GTG TCA GGC ATA AGA TCT ATG ACAA 3' Forward primer in intron 2 of Xpa  gene
XP47 5' AGG CAA GCA CCT GCA GCT GT 3' Reverse primer spanning intron 3 and exon 3 of Xpa  gene
PGK2 5' GGC CAC TTG TGT AGC GCC AA 3' Reverse primer in PGK2 promoter of Neo-resistance cassette
Hupki Volume per reaction
Final concentration 
per reaction
Cycling parameters Product size
RedTaq 2X Ready Mix (Sigma #R2523) 6.25 µL 1X 94°C 1.5 minutes 1 cycle
IMR1732 (H) primer [10 µM] 0.5 µL 5 pmol 94°C 30 seconds Hupki : 172 bp
IMR1733 (H) primer [10 µM] 0.5 µL 5 pmol 66°C 1 minute
Ear clip DNA extract 2 µL 72°C 2 minutes
nuclease-free water 3.25 µL 72°C 2 minutes 1 cycle
final volume of 12.5 µL 4 - 10°C Hold
mouse 
Trp53
Volume per reaction
Final concentration 
per reaction
Cycling parameters Product size
RedTaq 2X Ready Mix (Sigma #R2523) 6.25 µL 1X 94°C 1.5 minutes 1 cycle
IMR1734 (M) primer [10 µM] 0.5 µL 5 pmol 94°C 30 seconds
IMR1735 (M) primer [10 µM] 0.5 µL 5 pmol 66°C 1 minute
Ear clip DNA extract 2 µL 72°C 2 minutes
nuclease-free water 3.25 µL 72°C 2 minutes 1 cycle
final volume of 12.5 µL 4 - 10°C Hold
Xpa Volume per reaction
Final concentration 
per reaction
Cycling parameters Product size
RedTaq 2X Ready Mix (Sigma #R2523) 6.25 µL 1X 94°C 1 minute
XP26 primer [10 µM] 1.0 µL 10 pmol 60°C 1 minute WT Xpa : 214 bp
XP47 primer [10 µM] 0.5 µL 5 pmol 70°C 2 minutes Null Xpa : 132 bp
PGK2 primer [10 µM] 0.5 µL 5 pmol 72°C 10 minutes 1 cycle
Ear clip DNA extract 2 µL 4 - 10°C Hold
nuclease-free water 2.25 µL 
final volume of 12.5 µL
PCR reaction 
components
35 cycles mouse Trp53 : 146 bp
PCR reaction 
components
35 cycles
Hupki
wild-type 
Trp53
Xpa
PCR reaction 
components
35 cycles
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Table S2. Primer sequences, PCR conditions and reference sequences for DNA sequencing 
exons 4–9 of Hupki TP53. For C: intronic sequence is lower case, exonic sequence is upper case, 
and primer binding sites are bold/underlined. 
 
A. Primer Information
TP53  Exon(s) Primer Name
Forward
/Reverse Primer sequence 5' > 3' Reaction
GCEx4F Forward GTC CTC TGA CTG CTC TTT TCA CCC ATC TAC PCR
GCEx4R Reverse GGG ATA CGG CCA GGC ATT GAA GTC TC PCR
HUPKI4RJ2 Reverse GAT ACG GCC AGG CAT TG sequencing
GCEx5F Forward CTT GTG CCC TGA CTT TCA ACT CTG TCT C PCR
GCEx6R Reverse GCC ACT GAC AAC CAC CCT TAA CCC CTC PCR
HUPKI6RJ2 Reverse GCC ACT GAC AAC CAC C sequencing
p53ex7F MH08 Forward AGA TCA CGC CAC TGC ACT C PCR
p53ex7R MH08 Reverse CCG GAA ATG TGA TGA GAG GT PCR & sequencing
p53ex8F MH08 Forward CAA GGG TGG TTG GGA GTA GA PCR & sequencing
p53ex9R MH08 Reverse GTC TCT GGC ATG CGA CTC TC PCR
Exon 4 
Exons 5 & 6 
Exon 7 
Exons 8 & 9 
B. PCR amplification
Volume per 
reaction
Final concentration 
per reaction
2X Ready Mix with Taq (Sigma #P4600) 12.5 µL 1X 94°C 4 minutes 1 cycle
Forward primer (10 µM stock) 2.0 µL 20 pmol 94°C 30 seconds
2.0 µL 20 pmol 60°C 30 seconds
2.0 µL 200 ng 72°C 1 minute
6.5 µL 72°C 7 minutes 1 cycle
4 - 10°C Hold
Exon 4 366 bp Exon 7 376 bp
Exon 5 - 6 478 bp Exon 8 - 9 498 bp
Expected products
40 cycles
PCR reaction components (all exons) Cycling parameters
Reverse primer
DNA (100 ng/µL)
nuclease-free water
C. Reference sequences for PCR Amplicons
Exon 4
Exon 5 - 6
Exon 7
Exon 8 - 9
gtcctctgactgctcttttcacccatctacagTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGT
TCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCCCGTGGCCCCTGCACCAGCAGCTCCTACA
CCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTC
CGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTGACTTGCACGgtcagttgccctgaggggctggcttccatgagacttcaatgcctggccgtatccc
cttgtgccctgactttcaactctgtctccttcctcttcctacagTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCTGTGCAG
CTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCAGTCACAGCACATGACGGAGGT
TGTGAGGCGCTGCCCCCACCATGAGCGCTGCTCAGATAGCGATGgtgagcagctggggctggagagacgacagggctggttgcccagggtccccaggcctctga
ttcctcactgattgctcttagGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGAAAC
ACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGgtctggtttgcaactggggtctctgggaggaggggttaagggtggttgtcagtggc  
agatcacgccactgcactccagcctgggcgacagagcgagattccatctcaaaaaaaaaaaaaaaaggcctcccctgcttgccacaggtctccccaaggcgcactggcctcatcttgggcctgtgttatctc
ctagGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATC
CTCACCATCATCACACTGGAAGACTCCAGgtcaggagccacttgccaccctgcacactggcctgctgtgccccagcctctgcttgcctctgacccctgggcccacctcttaccgatt
tcttccatactactacccatccacctctcatcacatttccgg  
caagggtggttgggagtagatggagcctggttttttaaatgggacaggtaggacctgatttccttactgcctcttgcttctcttttcctatcctgagtagTGGTAATCTACTGGGACGGAACA
GCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCA
CCACGAGCTGCCCCCAGGGAGCACTAAGCGAGgtaagcaagcaggacaagaagcggtggaggagaccaagggtgcagttatgcctcagattcacttttatcacctttccttgcc
tctttcctagCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGgtacta
agtcttgggacctcttatcaagtggaaagtttccagtctaacactcaaaatgccgt <human seq,   mouse seq> ggtaccaaggctggagagtcgcatgccagagac
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Table S3. Sequence context of TP53 mutations induced by BPDE in HUFs. For each type of 
single base substitution or deletion, the 5’ and 3’ base are shown. SA = splice acceptor site; CpG 
indicates the presence of a mutation at a methylated CpG site; NTS = nontranscribed strand; TS = 
transcribed strand. DNA strand indicates the strand of the G or A substitution. 
 
Clone ID*
Xpa 
Status Codon
WT codon 
(NTS)
MUT codon 
(NTS)
DNA 
strand
CpG 
site
G or A 
substitution 5' base 3' base
Coding 
Description
XN-BP-300 Null 131 AAC ACC NTS A:T > C:G A C c.392A>C
XN-BP-278 Null 211 ACT CCT NTS A:T > C:G C C c.631A>C
XN-BP-299 Null 265 CTG CGG TS A:T > C:G C G c.794T>G
XW-BP-38 WT 286 GAA GGA NTS A:T > G:C G A c.857A>G
XW-BP-10 WT 132 AAG ATG NTS A:T > T:A A G c.395A>T
XN-BP-229 Null 253 ACC TCC NTS A:T > T:A C C c.757A>T
XN-BP-292 Null 65 AGA TGA NTS A:T > T:A C G c.193A>T
XN-BP-255 Null 330 CTT _TT TS del. G A G c.988del1
XW-BP-73 WT 158 CGC _GC TS CpG del. G C G c.472del1
XN-BP-296 Null 267 CGG C_G NTS CpG del. G C G c.800del1
XN-BP-206 Null 189 GCC _CC NTS del. G G C c.565del1
XN-BP-257 Null 267 CGG C__ NTS CpG del. GG C A c.800del2
XN-BP-204 Null in. 6 (SA) NTS G:C > A:T A G c.673-1G>A
XW-BP-16 WT 248 CGG CAG NTS CpG G:C > A:T C G c.743G>A
XW-BP-55 WT 248 CGG CAG NTS CpG G:C > A:T C G c.743G>A
XN-BP-225 Null 157 GTC GTT TS G:C > A:T G A c.471C>T
XW-BP-91 WT 91 TGG TGA NTS G:C > A:T G C c.273G>A
XN-BP-204 Null 155 ACC ATC TS G:C > A:T G T c.464C>T
XN-BP-210 Null 272 GTG ATG NTS G:C > A:T G T c.814G>A
XN-BP-265 Null 242 TGC TAC NTS G:C > A:T T C c.725G>A
XW-BP-50 WT 143 GTG ATG NTS G:C > A:T T T c.427G>A
XW-BP-83 WT 224 GAG GAC NTS G:C > C:G A G c.672G>C
XW-BP-26 WT 181 CGC CCC NTS CpG G:C > C:G C C c.542G>C
XN-BP-237 Null 273 CGT GGT TS CpG G:C > C:G C C c.817C>G
XN-BP-273 Null 196 CGA GGA TS CpG G:C > C:G C G c.586C>G
XW-BP-42 WT 245 GGC CGC NTS CpG G:C > C:G C G c.733G>C
XN-BP-238 Null 282 CGG GGG TS CpG G:C > C:G C G c.844C>G
XN-BP-201 Null 110 CGT CCT NTS CpG G:C > C:G C T c.329G>C
XN-BP-274 Null 273 CGT CCT NTS CpG G:C > C:G C T c.818G>C
XW-BP-17 WT 195 ATC ATG TS G:C > C:G G A c.585C>G
XN-BP-300 Null 135 TGC TGG TS G:C > C:G G C c.405C>G
XW-BP-2 WT 249 AGG AGC NTS G:C > C:G G C c.747G>C
XN-BP-229 Null 34 CCC CCA TS G:C > T:A A G c.102C>A
XW-BP-17 WT 196 CGA CTA NTS CpG G:C > T:A C A c.587G>T
XW-BP-50 WT 213 CGA CTA NTS CpG G:C > T:A C A c.638G>T
XN-BP-225 Null 158 CGC CTC NTS CpG G:C > T:A C C c.473G>T
XN-BP-228 Null 158 CGC CTC NTS CpG G:C > T:A C C c.473G>T
XN-BP-251 Null 273 CGT AGT TS CpG G:C > T:A C C c.817C>A
XW-BP-95 WT 248 CGG CTG NTS CpG G:C > T:A C G c.743G>T
XN-BP-268 Null 157 GTC TTC NTS CpG G:C > T:A C T c.469G>T
XW-BP-6 WT 273 CGT CTT NTS CpG G:C > T:A C T c.818G>T
XW-BP-63 WT 273 CGT CTT NTS CpG G:C > T:A C T c.818G>T
XN-BP-294 Null 127 TCC TAC TS G:C > T:A G A c.380C>A
XN-BP-238 Null 171 GAG TAG NTS G:C > T:A G A c.511G>T
XW-BP-83 WT 154 GGC GTC NTS G:C > T:A G C c.461G>T
XN-BP-206 Null 188 CTG CTT NTS G:C > T:A T G c.564G>T
XW-BP-2 WT 203 GTG TTG NTS G:C > T:A T T c.607G>T
XN-BP-254 Null 274 GTT TTT NTS G:C > T:A T T c.820G>T
XW-BP-9 WT 275 TGT TTT NTS G:C > T:A T T c.824G>T
* XW = Xpa-WT; XN = Xpa-Null; BP = BPDE-treated; C = control
43 
 
Table S4. The occurrence in human cancer of TP53 mutations found in BPDE-treated HUFs. 
 
Clone ID*
Coding 
Description
Coding 
change Codon #
Lung cancer, 
smokers***
Lung cancer, non-
smokers**** All cancer CpG
XN-BP-229 c.102C>A (silent) P34P 34 0 (0) 0 (0) 0 (4)
XN-BP-292 c.193A>T R65stop 65 2 (2) 0 (0) 4 (6)
XW-BP-91 c.273G>A W91stop 91 0 (1) 0 (1) 12 (30)
XN-BP-201 c.329G>C R110P 110 1 (6) 0 (0) 15 (76) CpG
XN-BP-294 c.380C>A S127Y 127 1 (4) 0 (2) 11 (66)
XN-BP-300 c.392A>C N131T 131 0 (3) 0 (1) 0 (62)
XW-BP-10 c.395A>T R132M 132 1 (13) 0 (2) 14 (217)
XN-BP-300 c.405C>G C135W 135 2 (6) 1 (4) 28 (267)
XW-BP-50 c.427G>A V143M 143 1 (4) 0 (0) 35 (96)
XW-BP-83 c.461G>T G154V 154 7 (12) 1 (1) 67 (129)
XN-BP-204 c.464C>T T155I 155 2 (8) 0 (0) 21 (128)
XN-BP-268 c.469G>T V157F 157 24 (30) 1 (3) 210 (313) CpG
XN-BP-225 c.471C>T (silent) V157V 157 0 (30) 0 (3) 5 (313)
XW-BP-73 c.472del1 frameshift 158 1 (44) 0 (5) 8 (326) CpG
XN-BP-225, -228 c.473G>T R158L 158 32 (44) 1 (5) 102 (326) CpG
XN-BP-238 c.511G>T E171stop 171 3 (5) 0 (0) 22 (65)
XW-BP-26 c.542G>C R181P 181 2 (3) 0 (0) 24 (106) CpG
XN-BP-206 c.564G>T (silent) L188L 188 0 (2) 0 (0) 0 (14)
XN-BP-206 c.565del1 frameshift 189 1 (2) 0 (0) 2 (34)
XW-BP-17 c.585C>G I195M 195 0 (9) 0 (2) 0 (196)
XW-BP-17 c.587G>T R196L 196 0 (7) 0 (3) 2 (289) CpG
XN-BP-273 c.586C>G R196G 196 0 (7) 1 (3) 3 (289) CpG
XW-BP-2 c.607G>T V203L 203 0 (0) 0 (0) 8 (49)
XN-BP-278 c.631A>C T211P 211 0 (0) 0 (0) 1 (59)
XW-BP-50 c.638G>T R213L 213 1 (5) 1 (6) 41 (435) CpG
XW-BP-83 c.672G>C E224D 224 0 (3) 0 (1) 9 (58)
XN-BP-265 c.725G>A C242Y 242 3 (9) 2 (6) 56 (237)
XW-BP-42 c.733G>C G245R 245 5 (43) 2 (5) 19 (866) CpG
XW-BP-16, -55 c.743G>A R248Q 248 15 (56) 6 (11) 933 (1880) CpG
XW-BP-95 c.743G>T R248L 248 23 (56) 1 (11) 121 (1880) CpG
XW-BP-2 c.747G>C R249S 249 0 (32) 0 (6) 42 (719)
XN-BP-229 c.757A>T T253S 253 0 (1) 0 (0) 5 (49)
XN-BP-299 c.794T>G L265R 265 0 (1) 0 (1) 5 (58)
XN-BP-296 c.800del1 frameshift 267 0 (7) 0 (2) 3 (86) CpG
XN-BP-257 c.800del2 frameshift 267 0 (7) 0 (2) 0 (86) CpG
XN-BP-210 c.814G>A V272M 272 3 (7) 1 (2) 114 (211)
XN-BP-237 c.817C>G R273G 273 3 (62) 0 (17) 19 (1814) CpG
XN-BP-251 c.817C>A R273S 273 3 (62) 0 (17) 19 (1814) CpG
XW-BP-6, -63 c.818G>T R273L 273 30 (62) 4 (17) 155 (1814) CpG
XN-BP-274 c.818G>C R273P 273 2 (62) 0 (17) 38 (1814) CpG
XN-BP-254 c.820G>T V274F 274 3 (5) 1 (1) 34 (118)
XW-BP-9 c.824G>T C275F 275 4 (9) 1 (3) 54 (193)
XN-BP-238 c.844C>G R282G 282 2 (16) 0 (5) 48 (715) CpG
XW-BP-38 c.857A>G E286G 286 1 (12) 0 (1) 20 (176)
XN-BP-255 c.988del1 frameshift 330 0 (1) 0 (0) 1 (13)
XN-BP-204 c.673-1G>A splice in. 6 
(SA)
0 (6) 0 (0) 12 (69)
# of tumours harbouring mutation (codon) **
* XW = Xpa-WT; XN = Xpa-Null; BP = BPDE-treated; C = control; ** Reference data: IARC TP53 Mutation Database, R17
(November 2013). *** Lung cancer in smokers (exclusions: radon, asbestos, mustard gas, and coal [3, 4]; **** Lung cancer in
non- and passive-smokers (exclusions: radon, asbestos, mustard gas, and coal [3, 4].
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Table S5. Comparison of TP53 mutations generated in the current study with mutations 
identified in all previous HIMAs. Exact mutation matches, as well as codons mutated in previous 
HIMAs, are indicated with an ‘x’ and are also in bold. The number of HUF cell lines in which a 
mutation previously occurred is shown. 3-NBA = 3-nitrobenzanthrone; BaP = benzo[a]pyrene; AAI 
= aristolochic acid I; UV = ultraviolet irradiation; MNNG: 1-methyl-2-nitro-1-nitrosoguanidine; 
control = spontaneously immortalised, untreated.  
 
Treatment WT codon
Mutant 
codon
Base change Codon
Occurrence: 
HUF cell lines
Reference
Codon mutated in 
current study
Mutation match 
with current study
3-NBA CGC CGA G:C>T:A 72 1 vom Brocke 2009
3-NBA CCT CAT G:C>T:A 128 1 vom Brocke 2009
3-NBA TAC TGC A:T>G:C 163 4 vom Brocke 2009
3-NBA GTG TTG G:C>T:A 173 1 vom Brocke 2009
3-NBA TGC TGG G:C>C:G 176 1 vom Brocke 2009
3-NBA ATC TTC A:T>T:A 195 1 vom Brocke 2009 x
3-NBA CGA CTA G:C>T:A 196 1 vom Brocke 2009 x x
3-NBA TAT AAT A:T>T:A 205 1 vom Brocke 2009
3-NBA TTG GTG A:T>C:G 206 1 vom Brocke 2009
3-NBA TAC TGC A:T>G:C 236 2 vom Brocke 2009
3-NBA GGC GCC G:C>C:G 244 2 vom Brocke 2009
3-NBA GGC GCC G:C>C:G 245 2 vom Brocke 2009 x
3-NBA ATG AAG A:T>T:A 246 1 vom Brocke 2009
3-NBA AAC ACC A:T>C:G 247 1 vom Brocke 2009
3-NBA ACA AAA G:C>T:A 256 1 vom Brocke 2009
3-NBA TTT GTT A:T>C:G 270 1 vom Brocke 2009
3-NBA CGT CTT G:C>T:A 273 1 vom Brocke 2009 x x
3-NBA GTT TTT G:C>T:A 274 2 vom Brocke 2009 x x
3-NBA AGA ATA G:C>T:A 280 1 vom Brocke 2009
BaP GGG TGG G:C>T:A 117 1 Liu 2005
BaP GCC GGC G:C>C:G 119 1 Reinbold 2007
BaP TGC TGG G:C>C:G 135 1 Reinbold 2007 x x
BaP GCC GGC G:C>C:G 138 1 Liu 2005
BaP TGC TGG G:C>C:G 141 1 Reinbold 2007
BaP CAG CAT G:C>T:A 144 1 Reinbold 2007
BaP GTC GTT G:C>A:T 157 2 Liu 2005 x x
BaP GTC TTC G:C>T:A 157 3 Liu 2005, Reinbold 2007 x x
BaP CGC CCC G:C>C:G 158 1 Liu 2005 x
BaP CGC CTC G:C>T:A 158 1 Liu 2005 x x
BaP GAA TAA G:C>T:A 198 1 Unpublished
BaP GTG TTG G:C>T:A 216 1 Reinbold 2007
BaP GAG GAA G:C>A:T 224 1 Liu 2005 x
BaP CGG CCG G:C>C:G 248 1 Reinbold 2007 x
BaP CGT GGT G:C>C:G 273 1 Reinbold 2007 x x
BaP CGT TGT G:C>A:T 273 1 Reinbold 2007 x x
BaP CGT CAT G:C>A:T 273 1 Liu 2005 x
BaP CGT CTT G:C>T:A 273 2 Reinbold 2007 x
BaP CCT TCT G:C>A:T 278 1 Liu 2005
BaP GGG TGG G:C>T:A 279 1 Liu 2005
BaP AGA GGA A:T>G:C 280 1 Liu 2005
BaP GAC GAA G:C>T:A 281 1 Reinbold 2007
BaP CGG CTG G:C>T:A 282 1 Reinbold 2007 x
AAI ACT TCT A:T>T:A 55 1 Nedelko 2009
AAI CAG CTG A:T>T:A 104 1 Nedelko 2009
AAI CTC CAC A:T>T:A 130 1 Feldmeyer 2006
AAI AAC TAC A:T>T:A 131 1 Nedelko 2009 x
AAI AAC ATC A:T>T:A 131 1 Nedelko 2009 x
AAI TGC TGG G:C>C:G 135 3 Nedelko 2009 x x
AAI AAG TAG A:T>T:A 139 1 Feldmeyer 2006
AAI GGC GTC G:C>T:A 154 1 Nedelko 2009 x x
AAI CGC GGC G:C>C:G 158 1 Liu 2004 x
AAI GCC CCC G:C>C:G 159 1 Nedelko 2009
AAI AAG TAG A:T>T:A 164 1 Nedelko 2009
AAI CAC CAG G:C>C:G 168 1 Nedelko 2009
AAI ATG TTG A:T>T:A 169 1 Nedelko 2009
AAI TGC TGG G:C>C:G 176 1 Liu 2004
AAI CAT CGT A:T>G:C 179 1 Nedelko 2009
AAI CAT CTT A:T>T:A 193 1 Feldmeyer 2006
AAI CTT TTT G:C>A:T 194 1 Nedelko 2009
AAI GTG GTC G:C>C:G 203 1 Feldmeyer 2006 x
AAI AGA TGA A:T>T:A 209 3 Liu 2004, Nedelko 2009
AAI CGA CCA G:C>C:G 213 1 Nedelko 2009 x
AAI AAC GAC A:T>G:C 239 1 Nedelko 2009
AAI GGC GCC G:C>C:G 245 1 Nedelko 2009 x
AAI AGG TGG A:T>T:A 249 2 Nedelko 2009 x
AAI GAA GAC A:T>C:G 258 1 Nedelko 2009
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Table S5 continued. 
 
Treatment WT codon
Mutant 
codon
Base change Codon
Occurrence: 
HUF cell lines
Reference
Codon mutated in 
current study
Mutation match 
with current study
AAI CGT TGT G:C>A:T 273 1 Nedelko 2009 x
AAI AGA AGT A:T>T:A 280 1 Liu 2004
AAI GAC GTC A:T>T:A 281 1 Liu 2004
AAI GAA GTA A:T>T:A 286 1 Feldmeyer 2006 x
AAI AAG TAG A:T>T:A 291 1 Nedelko 2009
AAI AAG TAG A:T>T:A 305 1 Nedelko 2009
AAI AGC TGC A:T>T:A 313 1 Feldmeyer 2006
UV TGC TGG G:C>C:G 135 1 Liu 2004 x x
UV CCC TCC G:C>A:T 151 1 Liu 2004
UV CAT TAT G:C>A:T 179 1 Liu 2004
UV CGG CAG G:C>A:T 248 1 Liu 2004 x x
UV AGG AGA G:C>A:T 249 1 Liu 2004 x
UV CCC CAC G:C>T:A 250 1 Liu 2004
UV CAG TAG G:C>A:T 317 1 Liu 2004
MNNG TCC TTC C to T 99 1 Nedelko 2009
MNNG TTC GTC T to G 113 1 Nedelko 2009
MNNG TGC TAC G to A 141 1 Nedelko 2009
MNNG CCG TCG C to T 152 1 Nedelko 2009
MNNG GCC GTC C to T 159 1 Nedelko 2009
MNNG CAG TAG C to T 165 1 Nedelko 2009
MNNG TCC TTC C to T 241 1 Nedelko 2009
MNNG TCC TTC C to T 241 1 Nedelko 2009
MNNG GGC GAC G to A 245 1 Nedelko 2009 x
MNNG GTG ATG G to A 272 1 Nedelko 2009 x x
MNNG GAC GAG C to G 281 1 Nedelko 2009
MNNG CGG TGG C to T 282 1 Nedelko 2009 x
MNNG AAA TAA A to T 321 1 Nedelko 2009
control GGC GCC G:C>C:G 105 1 Whibley 2010
control TTC GTC A:T>C:G 113 2 Whibley 2010
control AAG ACG A:T>C:G 120 1 Whibley 2010
control AAG ACG A:T>C:G 132 1 Whibley 2010 x
control TTT GTT A:T>C:G 134 2 Whibley 2010
control TGC TGG G:C>C:G 135 7 Whibley 2010 x x
control GCC CCC G:C>C:G 138 2 Whibley 2010
control AAG AAC G:C>C:G 139 1 Whibley 2010
control GTG ATG G:C>A:T 143 1 Whibley 2010 x x
control GTT GGT A:T>C:G 147 3 Whibley 2010
control GCC CCC G:C>C:G 159 1 Whibley 2010
control GCC GGC G:C>C:G 161 1 Whibley 2010
control GCC CCC G:C>C:G 161 1 Whibley 2010
control GTG ATG G:C>A:T 173 1 Whibley 2010
control CGC CAC G:C>A:T 175 1 Whibley 2010
control TGC TGG G:C>C:G 176 2 Whibley 2010
control TGC TAC G:C>A:T 176 1 Whibley 2010
control TGC TTC G:C>T:A 176 1 Whibley 2010
control CAT TAT G:C>A:T 179 1 Whibley 2010
control CTT TTT G:C>A:T 194 1 Whibley 2010
control ATC ACC A:T>G:C 195 1 Whibley 2010 x
control GTG CTG G:C>C:G 216 1 Whibley 2010
control AAC AGC A:T>G:C 239 1 Whibley 2010
control AGT AGG A:T>C:G 240 1 Whibley 2010
control GGC GAC G:C>A:T 245 2 Whibley 2010 x
control GGC GCC G:C>C:G 245 5 Whibley 2010 x
control ATG AAG A:T>T:A 246 1 Whibley 2010
control AGG AGC G:C>C:G 249 2 Whibley 2010 x x
control ATC AGC A:T>C:G 255 2 Whibley 2010
control GAA GAC A:T>C:G 258 1 Whibley 2010
control CTG CCG A:T>G:C 265 1 Whibley 2010 x
control CGT GGT G:C>C:G 273 2 Whibley 2010 x x
control CGT TGT G:C>A:T 273 2 Whibley 2010 x
control TGT TTT G:C>T:A 275 1 Whibley 2010 x x
control GCC GGC G:C>C:G 276 1 Whibley 2010
control AGA ACA G:C>C:G 280 1 Whibley 2010
control GAC GAG G:C>C:G 281 3 Whibley 2010
control GAC AAC G:C>A:T 281 1 Whibley 2010
control GAC CAC G:C>C:G 281 2 Whibley 2010
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Figure S1. Metabolic activation of BaP to the reactive intermediate BPDE and subsequent 
DNA adduct formation. BaP is first oxidised by CYP1A1 and CYP1B1 to form BaP-7,8-epoxide, 
which is then converted to BaP-7,8-dihydrodiol by mEH. Further oxidation by CYP1A1/CYP1B1 
leads to the formation of the ultimate reactive species, BPDE. BPDE preferentially reacts with 
guanine residues in DNA, and the 10-(deoxyguanosin-N
2
-yl)7,8,9-trihydroxy-7,8,9,10-tetrahydro-
BaP (BPDE-N
2
-dG) adduct is the major adduct formed by BPDE both in vitro and in vivo. CYP, 
cytochrome P450; mEH, microsomal epoxide hydrolase. 
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Figure S2. BPDE-N
2
-dG adduct levels in Xpa-WT and Xpa-Null Hupki mice assessed 5 days 
after a single treatment with BaP. Mice were treated with 125 mg/kg bw BaP and DNA adduct 
levels in different tissues were assessed by 
32
P-postlabelling. Values represent means ± SD from 3 
animals, and each DNA sample was measured by two independent 
32
P-postlabelling analyses. † = 
not determined due to death of Xpa-Null animals.  
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Figure S3. DNA adduct pattern induced in Xpa-WT and Xpa-Null Hupki mice treated with 
BaP. Autoradiographic profiles of DNA adducts obtained in mice treated with (A) 125 or (B) 12.5 
mg/kg bw BaP, as indicated, and adducts in different tissues were detected by 
32
P-postlabelling; the 
origins, in the bottom left-hand corner, were cut off before exposure. The major DNA adduct 
detected in all tissues examined was previously identified as 10-(deoxyguanosin-N
2
-yl)-7,8,9-
trihydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE-N
2
-dG) [1]. Adduct spot 2 was previously 
suggested to be derived from reaction of 9-hydroxy-BaP-4,5-epoxide with guanine [2]. Adduct spot 
3 has not yet been structurally identified.  
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Figure S4. Growth of HUFs at 20% O2 following one week of culture at 3% O2. Xpa-WT and 
Xpa-Null primary HUFs (2.5  105 cells/ 25-cm2 flask) were cultured for one week at 3% O2 and 
then transferred to 20% O2 for a further five weeks of culture. Cells were counted every 3–4 days, 
diluted and reseeded to determine the cumulative population doublings over time. 
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Figure S5. BPDE-DNA adduct repair in Xpa-WT and Xpa-Null HUFs. HUFs were exposed to 
0.25 μM BPDE for up to 2 hr. Treated cells were harvested following 0.5 hr and 2 hr of exposure, 
or BPDE was removed and replaced with normal growth medium. In the latter case, cells were 
cultured for an additional 4 hr, and then harvested. Harvested cells were assessed for BPDE-N
2
-dG 
adduct formation by 
32
P-postlabelling. Values represent means ± SD of two separate experiments 
where each DNA sample was measured by two independent 
32
P-postlabelling analyses. Statistical 
analysis, comparing DNA adduct levels in Xpa-WT and Xpa-Null HUFs, was performed by 2-
factor ANOVA followed by Bonferroni’s post-hoc contrasts; * P < 0.05, ** P < 0.01. 
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